

Approved



Democratic Republic of the Congo

Country Operational Plan

FY 2014

Note: *Italicized sections of narrative text indicate that the content was not submitted in the Lite COP year, but was derived from the previous Full COP year. This includes data in Technical Area Narratives, and Mechanism Overview and Budget Code narratives from continued mechanisms.*



Budget Summary Reports

Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Total
	GAP	GHP-State	GHP-USAID	
DOD		2,420,000		2,420,000
HHS/CDC	825,000	25,379,954		26,204,954
State		300,000		300,000
State/AF		460,000		460,000
USAID		23,415,046	9,200,000	32,615,046
Total	825,000	51,975,000	9,200,000	62,000,000

Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency						On Hold Amount	Total
	State	DOD	HHS/CDC	State/AF	USAID	AllOther		
HBHC		320,000	3,638,362		5,362,803		0	9,321,165
HKID		230,000	292,794		4,536,965		0	5,059,759
HLAB		70,000	876,419		819,405		0	1,765,824
HMBL			333,782		0		0	333,782
HMIN		150,000	107,506		0		0	257,506
HTXD			9,758		3,256,885		0	3,266,643
HTXS		200,000	2,988,084		3,469,228		0	6,657,312
HVAB	2,915	230,000	22,521	50,000	259,055		0	564,491
HVCT		200,000	344,057		1,491,352		0	2,035,409
HVMS	232,961	0	2,968,827		571,709		0	3,773,497
HVOP	17,488	350,000	1,025,238	200,000	1,750,231		0	3,342,957
HVSI		50,000	2,090,530		549,207		0	2,689,737
HVTB		150,000	2,664,195		2,156,925		0	4,971,120
MTCT	23,318		5,313,371	210,000	2,946,886		0	8,493,575
OHSS	23,318	150,000	691,434		1,565,754		0	2,430,506
PDCS		200,000	1,941,075		2,422,321		0	4,563,396

Approved



PDTX		120,000	897,001		1,456,320		0	2,473,321
	300,000	2,420,000	26,204,954	460,000	32,615,046	0	0	62,000,000



Budgetary Requirements Worksheet

Redacted

Technical Areas

Technical Area Summary

Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
HBHC	9,154,718	0
HKID	4,967,349	0
HVTB	4,843,138	0
PDCS	4,491,839	0
Total Technical Area Planned Funding:	23,457,044	0

Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	1,564,500	0
HVSI	2,286,000	0
OHSS	1,995,000	0
Total Technical Area Planned Funding:	5,845,500	0

Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
HMBL	300,000	0
HMIN	250,000	0
HVAB	530,000	0
HVCT	1,958,372	0

Approved



HVOP	3,258,894	0
MTCT	8,191,952	0
Total Technical Area Planned Funding:	14,489,218	0

Technical Area: Treatment

Budget Code	Budget Code Planned Amount	On Hold Amount
HTXD	3,183,301	0
HTXS	6,585,457	0
PDTX	2,439,480	0
Total Technical Area Planned Funding:	12,208,238	0



Technical Area Summary Indicators and Targets

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	6,044	6,498
	By program area/support type: HTC Direct Service Delivery (DSD)	687	744
	By program area/support type: HTC Technical Assistance-only (TA)	0	0
	By program area/support type: Treatment Direct Service Delivery (DSD)	673	731
	By program area/support type: Treatment Technical Assistance-only (TA)	109	111
	By program area/support type: Care and Support Direct Service Delivery (DSD)	693	751
	By program area/support type: Care and Support Technical Assistance-only (TA)	8	10
	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	480	669
	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	10	50



	By program area/support type: PMTCT Direct Service Delivery (DSD)	631	730
	By program area/support type: PMTCT Technical Assistance-only (TA)	0	0
	By program area/support type: TB/HIV Direct Service Delivery (DSD)	654	715
	By program area/support type: TB/HIV Technical Assistance-only (TA)	0	0
	By program area/support type: VMMC Direct Service Delivery (DSD)	0	0
	By program area/support type: VMMC Technical Assistance-only (TA)	0	0
	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	202	245
	By program area/support type: General Population Prevention Technical Assistance-only (TA)	0	0
	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	168	183
	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	1	2
	By program area/support	315	0



	type: OVC Direct Service Delivery (DSD)		
	By program area/support type: OVC Technical Assistance-only (TA)	3	3
	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	587	745
	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	0	0
	By program area/support type: Lab Direct Service Delivery (DSD)	688	746
	By program area/support type: Lab Technical Assistance-only (TA)	10	10
PMTCT_SITE	PMTCT_SITE Percentage of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	n/a	
	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women		625
	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)		730
	By site support type: Direct Service Delivery (DSD):		625



	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women		
	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women		0
	Sum of Numerator Support Type disaggregates		625
	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)		730
	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)		0
	Sum of Denominator Support Type disaggregates		730
PMTCT_STAT_DSD	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	96 %	
	Number of pregnant women	372,605	396,934



	with known HIV status (includes women who were tested for HIV and received their results)		
	Number of new ANC and L&D clients	390,016	418,428
	By: Known positives at entry	1,017	1,089
	By: Number of new positives identified	5,869	6,236
	Sum of Positives Status disaggregates	6,886	7,325
	Required only for DREAMS Countries - By Number of new positives: <15		
	Required only for DREAMS Countries - By Number of new positives: 15-19		
	Required only for DREAMS Countries - By Number of new positives: 20-24		
	Required only for DREAMS Countries - By Number of new positives: 25+		
	Required only for DREAMS Countries - By Number of known positives: <15		
	Required only for DREAMS Countries - By Number of known positives: 15-19		
	Required only for DREAMS Countries - By Number of known positives: 20-24		
	Required only for DREAMS Countries - By Number of known positives: 25+		



	Required only for DREAMS Countries - Denominator: <15		
	Required only for DREAMS Countries - Denominator: <15-19		
	Required only for DREAMS Countries - Denominator: 20-24		
	Required only for DREAMS Countries - Denominator: 25+		
PMTCT_STAT_NGI	PMTCT_STAT_NGI Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (NGI)	96 %	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	372,605	
	Number of new ANC and L&D clients	390,016	
	By: Known positives at entry	1,017	
	By: Number of new positives identified	5,869	
	Sum of Positives Status disaggregates	6,886	
PMTCT_ARV_DSD	PMTCT_ARV_DSD Percentage of HIV-positive pregnant women who received antiretrovirals to reduce risk for	94 %	



	mother-to-child-transmission (MTCT) during pregnancy and delivery (DSD)		
	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	6,501	6,891
	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	6,886	7,325
	Life-long ART (including Option B+)	3,528	6,886
	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	2,337	4,614
	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	1,191	2,272
	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0
	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	2,973	5
	Single-dose nevirapine (with or without tail)	0	0



	Sum of Regimen Type disaggregates	6,501	6,891
	Sum of New and Current disaggregates	3,528	6,886
PMTCT_ARV_NGI	PMTCT_ARV_NGI Percentage of HIV-positive pregnant women who received antiretrovirals to reduce risk for mother-to-child-transmission (MTCT) during pregnancy and delivery (NGI)	94 %	
	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	6,501	
	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	6,886	
	Life-long ART (including Option B+)	3,528	
	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	2,337	
	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	1,191	
	Maternal triple ARV prophylaxis (provided with	0	



	the intention to stop at the end of the breastfeeding period)		
	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	2,973	
	Single-dose nevirapine (with or without tail)	0	
	Sum of Regimen disaggregates	6,501	
	Sum of New and Current disaggregates	3,528	
BS_COLL	Number of whole blood collections each year by the NBTS network	20,000	
	By: Number of whole blood donations screened for HIV in an NBTS network laboratory	20,000	
	By: Number of whole blood donations screened for HIV in an NBTS network laboratory that are identified as reactive for HIV	320	
PP_PREV_DSD	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	32 %	
	Number of the target population who completed a standardized HIV prevention	570,411	172,909



	intervention including the minimum components during the reporting period.		
	Total number of people in the target population	1,760,944	6,526,208
	Age/sex: 10-14 Male	16,810	6,519
	Age/sex: 15-19 Male	28,407	16,600
	Age/sex: 20-24 Male	176,656	23,069
	Age/sex: 25-49 Male	98,554	36,120
	Age/sex: 50+ Male	28,612	3,584
	Age/sex: 10-14 Female	8,172	6,105
	Age/sex: 15-19 Female	90,546	15,255
	Age/sex: 20-24 Female	57,520	23,227
	Age/sex: 25-49 Female	56,718	37,382
	Age/sex: 50+ Female	8,416	5,048
	Sum of Age/Sex disaggregates	570,411	172,909
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a	
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	10,662	17,111
	Total estimated number of key population in the		



	catchment area		
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	9,570	15,878
	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	9	13
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0
	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group	600	963



	level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)		
	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	483	257
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: Men who have sex with men/Transgender (MSM/TG)		



	(Denominator: Total estimated number of key population in the catchment area)		
	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Denominator: Total estimated number of key population in the catchment area)		
KP_PREV_TA	KP_PREV_TA Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (TA-only)	n/a	
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	478	1,384
	Total estimated number of key population in the catchment area		
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based	478	1,048



	on evidence and/or meet the minimum standards required)		
	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0
	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	179
	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key	0	157



	populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)		
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: Men who have sex with men/Transgender (MSM/TG) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Denominator: Total		



	estimated number of key population in the catchment area)		
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	606,808	666,900
	By Test Result: Negative	586,213	637,021
	By Test Result: Positive	20,595	23,274
	Sum of Test Result disaggregates	606,808	660,295
	Test Result by Age and Sex: Positive: <1 Male		
	Test Result by Age and Sex: Positive: 1-4 Male		
	Test Result by Age and Sex: Positive: 5-9 Male		
	Test Result by Age and Sex: Positive: 10-14 Male		
	Test Result by Age and Sex: Positive: 15-19 Male		
	Test Result by Age and Sex: Positive: 20-24 Male		
	Test Result by Age and Sex: Positive: 25-49 Male		
	Test Result by Age and Sex: Positive: 50+ Male		
	Test Result by Age and Sex: Positive: <1 Female		
	Test Result by Age and Sex: Positive: 1-4 Female		
	Test Result by Age and Sex: Positive: 5-9 Female		



	Test Result by Age and Sex: Positive: 10-14 Female		
	Test Result by Age and Sex: Positive: 15-19 Female		
	Test Result by Age and Sex: Positive: 20-24 Female		
	Test Result by Age and Sex: Positive: 25-49 Female		
	Test Result by Age and Sex: Positive: 50+ Female		
	Test Result by Age and Sex: Negative: <1 Male		
	Test Result by Age and Sex: Negative: 1-4 Male		
	Test Result by Age and Sex: Negative: 5-9 Male		
	Test Result by Age and Sex: Negative: 10-14 Male		
	Test Result by Age and Sex: Negative: 15-19 Male		
	Test Result by Age and Sex: Negative: 20-24 Male		
	Test Result by Age and Sex: Negative: 25-49 Male		
	Test Result by Age and Sex: Negative: 50+ Male		
	Test Result by Age and Sex: Negative: <1 Female		
	Test Result by Age and Sex: Negative: 1-4 Female		
	Test Result by Age and Sex: Negative: 5-9 Female		
	Test Result by Age and Sex: Negative: 10-14 Female		



	Test Result by Age and Sex: Negative: 15-19 Female		
	Test Result by Age and Sex: Negative: 20-24 Female		
	Test Result by Age and Sex: Negative: 25-49 Female		
	Test Result by Age and Sex: Negative: 50+ Female		
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	12,723	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	107,359	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	13,760	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	472,966	
	Sum of Aggregated Age/Sex <15	26,483	
	Sum of Aggregated Age/Sex 15+	580,325	
	Sum of Aggregated Age/Sex disaggregates	606,808	
	Service Delivery Point by Result: Antenatal Clinic - All results		
	Service Delivery Point by Result: Antenatal Clinic - Positive		
	Service Delivery Point by Result: Antenatal Clinic - Negative		



	Service Delivery Point by Result: Labor & delivery - All results		
	Service Delivery Point by Result: Labor & delivery - Positive		
	Service Delivery Point by Result: Labor & delivery - Negative		
	Service Delivery Point by Result: Under 5 Clinic – All results		
	Service Delivery Point by Result: Under 5 Clinic - Positive		
	Service Delivery Point by Result: Under 5 Clinic - Negative		
	Service Delivery Point by Result: Maternal and Child Health Clinic – All Results		
	Service Delivery Point by Result: Maternal and Child Health Clinic - Positive		
	Service Delivery Point by Result: Maternal and Child Health Clinic - Negative		
	Service Delivery Point by Result: Tuberculosis – All results		
	Service Delivery Point by Result: Tuberculosis - Positive		
	Service Delivery Point by Result: Tuberculosis -		



	Negative		
	Service Delivery Point by Result: Sexually Transmitted Infections – All Results		
	Service Delivery Point by Result: Sexually Transmitted Infections - Positive		
	Service Delivery Point by Result: Sexually Transmitted Infections - Negative		
	Service Delivery Point by Result: Outpatient Department – All Results		
	Service Delivery Point by Result: Outpatient Department - Positive		
	Service Delivery Point by Result: Outpatient Department - Negative		
	Service Delivery Point by Result: Inpatient – All Results		
	Service Delivery Point by Result: Inpatient - Positive		
	Service Delivery Point by Result: Inpatient - Negative		
	Service Delivery Point by Result: HIV care and treatment clinic – All Results		
	Service Delivery Point by Result: HIV care and treatment clinic - Positive		
	Service Delivery Point by Result: HIV care and treatment clinic - Negative		



	Service Delivery Point by Result: Voluntary Medical Male Circumcision – All Results		
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Positive		
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Negative		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) – All Results		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Positive		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Negative		
	Service Delivery Point by Result: Voluntary Counseling & Testing (stand alone) – All Results		
	Service Delivery Point by Result: Voluntary Counseling & Testing (stand alone) – Positive		
	Service Delivery Point by Result: Voluntary Counseling & Testing (stand alone) – Negative		
	Service Delivery Point by		



	Result: Mobile – All Results		
	Service Delivery Point by Result: Mobile - Positive		
	Service Delivery Point by Result: Mobile - Negative		
	Service Delivery Point by Result: Home-based – All Results		
	Service Delivery Point by Result: Home-based - Positive		
	Service Delivery Point by Result: Home-based - Negative		
	Service Delivery Point by Result: Other – All Results		
	Service Delivery Point by Result: Other - Positive		
	Service Delivery Point by Result: Other - Negative		
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	606,808	666,900
	By Test Result: Negative	586,213	637,021
	By Test Result: Positive	20,595	23,274
	Sum of Test Result disaggregates	606,808	660,295
	Age/sex: <1 Male		2,297
	Age/sex: 1-4 Male		3,463
	Age/sex: 5-9 Male		4,070
	Age/sex: 10-14 Male		3,310
	Age/sex: 15-19 Male		9,032



	Age/sex: 20-24 Male		32,636
	Age/sex: 25-49 Male		88,186
	Age/sex: 50+ Male		26,434
	Age/sex: <1 Female		9,456
	Age/sex: 1-4 Female		4,005
	Age/sex: 5-9 Female		4,209
	Age/sex: 10-14 Female		7,746
	Age/sex: 15-19 Female		32,963
	Age/sex: 20-24 Female		129,256
	Age/sex: 25-49 Female		292,646
	Age/sex: 50+ Female		17,191
	Sum of Age/Sex disaggregates		666,900
	Aggregated Age/sex: <15 Male	12,723	
	Aggregated Age/sex: 15+ Male	107,359	
	Aggregated Age/sex: <15 Female	13,760	
	Aggregated Age/sex: 15+ Female	472,966	
	Sum of Aggregated Age/Sex <15	26,483	
	Sum of Aggregated Age/Sex 15+	580,325	
	Sum of Aggregated Age/Sex disaggregates	606,808	
GEND_GBV_DSD	Number of people receiving post-GBV care	1,612	1,046
	Age/Sex: <10 Male		
	Age/Sex: 10-14 Male		
	Age/Sex: 15-17 Male		
	Age/Sex: 18-24 Male		



	Age/Sex: 25+ Male		
	Age/Sex: <10 Female		
	Age/Sex: 10-14 Female		
	Age/Sex: 15-17 Female		
	Age/Sex: 18-24 Female		
	Age/Sex: 25+ Female		
	Sum of Age/Sex Disaggregates		
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)		
	By type of service: Sexual Violence (Post-Rape Care)		
	By PEP service provision (related to sexual violence services provided)		
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria		61,765
	Age/Sex: <10 Male		
	Age/Sex: 10-14 Male		
	Age/Sex: 15-19 Male		
	Age/Sex: 20-24 Male		
	Age/Sex: 25+ Male		
	Age/Sex: <10 Female		
	Age/Sex: 10-14 Female		
	Age/Sex: 15-19 Female		
	Age/Sex: 20-24 Female		
	Age/Sex: 25+ Female		
	By Age: 0-9		
	By Age: 10-14		
	By Age: 15-19		



	By Age: 20-24		
	By Age: 25+		
	Sum of Age disaggregates		
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	7,637	
	Age/Sex: <1 Male		
	Age/Sex: 1-4 Male		
	Age/Sex: 5-9 Male		
	Age/Sex: 10-14 Male		
	Age/Sex: 15-17 Male		
	By: Age/sex: Male 18-24		
	By: Age/sex: Male 25+		
	Age/Sex: <1 Female		
	Age/Sex: 1-4 Female		
	Age/Sex: 5-9 Female		
	Age/Sex: 10-14 Female		
	Age/Sex: 15-17 Female		
	By: Age/sex: 18-24 Female		
	By: Age/sex: 25+ Female		
	Sum of Age/Sex disaggregates		
	Required only for DREAMS countries - By service, age and sex: Education Support Female <1		
Required only for DREAMS countries - By service, age and sex: Education Support Female 1-4			
Required only for DREAMS			



	countries - By service, age and sex: Education Support Female 5-9		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+		
	Required only for DREAMS countries - By service, age and sex: Education Support Male <1		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 1-4		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 5-9		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14		



	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female <1		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 1-4		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 5-9		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver		



	Programs Female 18-24		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male <1		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 1-4		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 5-9		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+		
	Required only for DREAMS countries - By service, age		



	and sex: Social Protection Female <1		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 1-4		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 5-9		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 25+		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male <1		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 1-4		
	Required only for DREAMS		



	countries - By service, age and sex: Social Protection Male 5-9		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 25+		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female <1		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 1-4		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 5-9		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14		



	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male <1		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 1-4		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 5-9		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17		
	Required only for DREAMS countries - By service, age and sex: Economic		



	Strengthening Male 18-24		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+		
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	41,496	
	By Age/Sex: <15 Female	3,897	
	By Age/Sex: <15 Male	3,034	
	By Age/Sex: 15+ Female	22,918	
	By Age/Sex: 15+ Male	11,647	
	Sum of Age/Sex disaggregates	41,496	
	By Age: <15	6,931	
	By Age: 15+	34,565	
	Sum of Age disaggregates	41,496	
	By Sex: Female	26,802	
	By Sex: Male	14,694	
	Sum of Sex disaggregates	41,496	
	C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	41,096
By Age/Sex: <15 Female		3,397	
By Age/Sex: <15 Male		3,134	
By Age/Sex: 15+ Female		24,918	
By Age/Sex: 15+ Male		9,647	
Sum of Age/Sex disaggregates		41,096	
By Age: <15		14,268	
By Age: 15+		26,828	



	Sum of Age disaggregates	41,096	
	By Sex: Female	28,302	
	By Sex: Male	12,794	
	Sum of Sex disaggregates	41,096	
C2.4.D_DSD	C2.4.D_DSD TB/HIV: Percent of HIV-positive patients who were screened for TB in HIV care or treatment setting	69 %	
	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	28,558	
	Number of HIV-positive individuals receiving a minimum of one clinical service	41,496	
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	38,759	48,838
	Age/sex: <1 Male		378
	Age/sex: 1-4 Male		324
	Age/sex: 5-9 Male		487
	Age/sex: 10-14 Male		325
	Age/sex: 15-19 Male		625
	Age/sex: 20-24 Male		1,532
	Age/sex: 25-49 Male		9,118
	Age/sex: 50+ Male		2,218
	Age/sex: <1 Female		919
	Age/sex: 1-4 Female		590



	Age/sex: 5-9 Female		485
	Age/sex: 10-14 Female		309
	Age/sex: 15-19 Female		1,626
	Age/sex: 20-24 Female		4,848
	Age/sex: 25-49 Female		22,001
	Age/sex: 50+ Female		3,053
	Sun of Age/Sex disaggregates		48,838
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,288	0
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	9,906	0
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,877	0
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	25,688	0
	Sum of Aggregated Age/Sex disaggregates	38,759	0
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load		25,531
	Age/sex: <1 Male		310
	Age/sex: 1-4 Male		150
	Age/sex: 5-9 Male		228



	Age/sex: 10-14 Male		215
	Age/sex: 15-19 Male		382
	Age/sex: 20-24 Male		891
	Age/sex: 25-49 Male		4,605
	Age/sex: 50+ Male		1,113
	Age/sex: <1 Female		564
	Age/sex: 1-4 Female		278
	Age/sex: 5-9 Female		250
	Age/sex: 10-14 Female		202
	Age/sex: 15-19 Female		1,003
	Age/sex: 20-24 Female		2,692
	Age/sex: 25-49 Female		11,130
	Age/sex: 50+ Female		1,518
	Sum of Age/sex disaggregates		25,531
	Aggregated Age/sex: <15 Male		
	Aggregated Age/sex: 15+ Male		
	Aggregated Age/sex: <15 Female		
	Aggregated Age/sex: 15+ Female		
	Sum of Aggregated Age/sex disaggregates		
CARE_SITE	CARE_SITE Percentage of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last	n/a	



	visit, AND 3) if eligible, cotrimoxazole		
	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole		703
	Total number of PEPFAR supported sites providing clinical care services		761
	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole		695
	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during		8



	the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole		
	Sum of Numerator Site Support Type disaggregates		703
	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services		751
	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing clinical care services		10
	Sum of Denominator Site Support Type disaggregates		761
FN_SITE	FN_SITE Percentage of PEPFAR-supported sites achieving 90% of nutrition assessments that result in an accurate categorization of malnutrition	n/a	
	Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition		306
	Total number of PEPFAR-supported sites providing nutrition		450



	assessment, counseling and support (NACS) services		
	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition		238
	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition		68
	Sum of Numerator Support Type disaggregates		306
	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services		364
	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services		86
	Sum of Denominator Support Type disaggregates		450



FN_THER_DSD	FN_THER_DSD Proportion of clinically undernourished PLHIV who received therapeutic or supplementary food	100 %	
	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	2,216	2,746
	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	2,216	2,774
	Age: <1		66
	Age: 1-4		126
	Age: 5-14		168
	Age: 15-17		142
	Age: 18+		2,244
	Sum of Age disaggregates		2,746
	Aggregated Age: <18	1,551	
	Aggregated Age: 18+	665	
	Sum of Aggregated Age disaggregates	2,216	
	By Pregnancy/Postpartum Status: Pregnant		
	By Pregnancy/Postpartum Status: Postpartum		
TB_ART_DSD	TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a	
	The number of registered new and relapse TB cases		4,007



	with documented HIV-positive status who are on ART during TB treatment during the reporting period		
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period		4,422
	Age: <1		
	Age: 1-4		
	Age: 5-9		
	Age: 10-14		
	Age: 15-19		
	Age: 20+		
	Sum of Age disaggregates		
	Male		1,526
	Female		2,481
	Sum of Sex disaggregates		4,007
	Newly tested		3,206
	Known HIV-positive		801
	Sum of Test Status disaggregates		4,007
	Aggregated Age: <15		
	Aggregated Age: 15+		
	Sum of Aggregated Age disaggregates		
	Timeliness: Art initiation <8 weeks of start of TB treatment		
	Timeliness: Art initiation >8 weeks of start of TB treatment		



TB_ARTSITE	TB_ARTSITE Proportion of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART	n/a	
	The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period		320
	The number of PEPFAR-supported TB basic management units		328
	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period		
	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period		
	Sum of Numerator Site Support Type disaggregates		



	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units		
	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units		
	Sum of Denominator Site Support Type disaggregates		
TB_SCREEN_DSD	TB_SCREEN_DSD Percentage of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period.	n/a	
	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period		40,278
	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	38,759	48,838
	Age: <1		
	Age: 1-4		
	Age: 5-9		
	Age: 10-14		
	Age: 15-19		



	Age: 20+		
	Sum of Age disaggregates		
	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15		
	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+		
	Sum of Aggregated Age disaggregates		
	Sex: Male		
	Sex: Female		
	Sum of Sex disaggregates		
PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	35 %	
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	2,437	2,870
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	6,886	7,325
	By infants who received a virologic test within 2 months of birth	1,690	2,188
	By infants who received their first virologic HIV test between 2 and 12 months of age	747	682



	Sum of Infant Age disaggregates	2,437	2,870
	By infants with a positive virologic test result within 12 months of birth	142	161
	Number of infants with a positive virological test result within 2 months of birth		
	Number of infants with a positive virological test result within 12 months of birth		
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	27,342	40,784
	Age/Sex: <1 Male		325
	Age/Sex: 1-4 Male		2,202
	Age/Sex: 5-14 Male		2,773
	Age/Sex: 15-19 Male		
	Age/Sex: 20+ Male		
	Age/Sex: <1 Female		325
	Age/Sex: 1-4 Female		2,195
	Age/Sex: 5-14 Female		2,984
	Age/Sex: 15-19 Female		
	Age/Sex: 20+ Female		
	Aggregated Age/Sex: <1 Male	74	
	Aggregated Age/Sex: <1 Female	77	
	Aggregated Age/Sex: 1-14 Male		
	Aggregated Age/Sex: 15+ Male	5,885	
	Aggregated Age/Sex: 1-14 Female		



	Aggregated Age/Sex: 15+ Female	15,556	
	Sum of Aggregated Age/Sex <15	5,901	
	Sum of Aggregated Age/Sex 15+	21,441	
	Sum of Aggregated Age/Sex disaggregates	27,342	
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	27,492	36,264
	Age/Sex: <1 Male		94
	Age/Sex: 1-4 Male		1,691
	Age/Sex: 5-14 Male		2,158
	Age/Sex: 15+ Male		8,230
	Age/Sex: <1 Female		94
	Age/Sex: 1-4 Female		1,685
	Age/Sex: 5-14 Female		2,265
	Age/Sex: 15+ Female		20,047
	Sum of Age/Sex disaggregates		36,264
	Aggregated Age/Sex: <1 Male	74	
	Aggregated Age/Sex: <1 Female	77	
	Aggregated Age/Sex: <15 Male	2,820	
	Aggregated Age/Sex: 15+ Male	5,958	
	Aggregated Age/Sex: <15 Female	3,081	
	Aggregated Age/Sex: 15+ Female	15,633	
	Sum of Aggregated Age/Sex	27,492	



	disaggregates		
	Sum of Aggregated Age/Sex <15	5,901	
	Sum of Aggregated Age/Sex 15+	21,591	
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	391	1,254
	Age/Sex: <1 Male		1
	Age/Sex: 1-4 Male		0
	Age/Sex: 5-14 Male		0
	Age/Sex: 15-19 Male		
	Age/Sex: 20+ Male		
	Age/Sex: <1 Female		1
	Age/Sex: 1-4 Female		0
	Age/Sex: 5-14 Female		1
	Age/Sex: 15-19 Female		
	Age/Sex: 20+ Female		
	Sum of Age/Sex disaggregations		3
	Aggregated Age/Sex: <1 Male	1	
	Aggregated Age/Sex: <1 Female	1	
	Aggregated Age/Sex: 1-14 Male		
	Aggregated Age/Sex: 15+ Male	113	
	Aggregated Age/Sex: 1-14 Female		
Aggregated Age/Sex: 15+ Female	268		
Sum of Aggregated Age/Sex	10		



	<15		
	Sum of Aggregated Age/Sex 15+	381	
	Sum of Aggregated Age/Sex disaggregates	391	
TX_DIST	TX_DIST Percentage of Districts that are PEPFAR supported with documented routine supportive supervision visits to 75% of ART sites in District	n/a	
	Number of Districts with documented routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District		141
	Total number of PEPFAR supported District Health Offices		141
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	11,213	20,409
	By Age/Sex: <1 Male		308
	By Age/Sex: 1-4 Male		1,148
	By Age/Sex: 5-9 Male		814
	By Age/Sex: 10-14 Male		642
	By Age/Sex: 15-19 Male		551
	By Age/Sex: 20-24 Male		423
	By Age/Sex: 25-49 Male		2,251
	By Age/Sex: 50+ Male		742
	By Age/Sex: <1 Female		312
	By Age/Sex: 1-4 Female		1,146
	By Age/Sex: 5-9 Female		923



	By Age/Sex: 10-14 Female		740
	By Age/Sex: 15-19 Female		748
	By Age/Sex: 20-24 Female		1,208
	By Age/Sex: 25-49 Female		7,658
	By Age/Sex: 50+ Female		795
	Sum of Age/Sex disaggregates		20,409
	Aggregated Grouping by Age: <1 Male	73	
	Aggregated Grouping by Age/Sex: 1-14 Male		
	Aggregated Grouping by Age/Sex: 15+ Male	2,289	
	Aggregated Grouping by Age/Sex: <1 Female	73	
	Aggregated Grouping by Age/Sex: 1-14 Female		
	Aggregated Grouping by Age/Sex: 15+ Female	5,554	
	Sum of Aggregated Age/Sex disaggregates	11,213	
	Pregnancy status	2,582	4,642
	Breastfeeding status	1,131	1,106
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	77 %	
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	8,962	15,615
	Total number of adults and children who initiated ART in	11,614	18,652



	the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up		
	Age/Sex: <5 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 5-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 20+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: <5 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		



	<p>Age/Sex: 5-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)</p>		
	<p>Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)</p>		
	<p>Age/Sex: 20+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)</p>		
	<p>Age/Sex: <5 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>		
	<p>Age/Sex: 5-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have</p>		



	stopped ART, and those lost to follow-up)		
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 20+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: <5 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 5-14 Female (Denominator: Total number of adults and children who initiated ART in the 12		



	months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 20+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Numerator by Status: Pregnant		
	Numerator by Status: Breastfeeding		
	Denominator by Status: Pregnant		
	Denominator by Status: Breastfeeding		
TX_SITE	TX_SITE Percentage of PEPFAR-supported ART	n/a	



	sites achieving a 75% ART retention rate		
	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation		416
	Total number of PEPFAR-supported ART sites		842
	By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation		
	By support type: Technical Assistance (TA-only): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation		
	Sum of Numerator Site Support Type disaggregates		
	By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites		731
	By support type: Technical Assistance (TA-only): Total		111



	number of PEPFAR-supported ART sites		
	Sum of Denominator Site Support Type disaggregates		842
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	5	19
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	698	757
	By clinical laboratories	407	408
	By Point-of-care testing sites	291	349
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program		506
	HIV serologic/diagnostic testing: Number of laboratories that perform this testing		
	HIV serologic/diagnostic testing: Number of		



	laboratories that participate in this PT program		
	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program		
	CD4: Number of laboratories that perform this testing		
	CD4: Number of laboratories that participate in this PT program		
	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program		
	Early infant diagnostics: Number of laboratories that perform this testing		
	Early infant diagnostics: Number of laboratories that participate in this PT program		
	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program		
	HIV viral load: Number of laboratories that perform this testing		
	HIV viral load: Number of laboratories that participate in this PT program		



	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program		
	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing		
	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program		
	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program		
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing		
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program		
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program		
	TB diagnostics (Culture/DST): Number of laboratories that perform this		



	testing		
	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program		
	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program		
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	2,264	2,232
	By Graduates: Doctors	17	17
	By Graduates: Nurses	2,135	2,135
	By Graduates: Midwives	97	97
	By Graduates: Social service workers	0	0
	By Graduates: Laboratory professionals	7	7
	By Graduates: Other	8	8
	Sum of Graduates disaggreagtes	2,264	2,264
SC_TRAIN	SC_TRAIN Percentage of individuals who received competency-based, certificate, or higher-level training to conduct or support supply chain, inventory	n/a	



	management, supportive supervision or distribution activities		
	Number of individuals who received competency-based, certificate or higher-level training to conduct or support supply chain, inventory management, supportive supervision or distribution activities		466
	Number of individuals who conduct or support supply chain, inventory management, supportive supervision or distribution activities		599
	By: Individuals trained in a nationally- or internationally-recognized pre-service training program		0
	By: Individuals who passed a competency-based training to conduct supply chain activities		6
	By: Individuals who passed a competency-based training to perform inventory management		274
	By: Individuals who passed a competency-based training to develop distribution plans		38
	By: Individuals who passed a competency-based training to perform supportive supervision		30



	By: Individuals who passed a competency-based training to perform quantification		118
FPINT_SITE_DSD	FPINT_SITE_DSD Family Planning and HIV Integration: Percentage of HIV service delivery points supported by PEPFAR that are directly providing integrated voluntary family planning services	n/a	
	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services		715
	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment		745
	Service delivery type: Care and Support		
	Service delivery type: Treatment		
	Service delivery type: PMTCT		
	Sum of Service delivery type (Care, Tx and PMTCT) disaggregates		
	QI_SITE	QI_SITE Percentage of PEPFAR-supported clinical service sites with quality improvement activities implemented that address	n/a



	clinical HIV program processes or outcomes and have documented process results in the last 6 months		
	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months		495
	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC		841
	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months		428
	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and		67



	has documented results in the last 6 months		
	Sum of Numerator Site Support Type disaggregates		495
	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC		745
	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC		96
	Sum of Denominator Site Support Type disaggregates		841
SC_STOCK	SC_STOCK Storage sites which stock commodities according to plan	n/a	
	Number of stock status observations for one or more tracer commodities that are between the designed minimum and maximum quantities/months of stock from storage sites within at a given level (Central, Regional, etc.) of the system.		1,099
	Total number of stock status observations for one or more		1,214



	tracer commodities from storage sites within at a given level (Central, Regional, etc.) of the system		
	System Level: Central Medical Stores		0
	System Level: Regional Medical Stores		1,037
	System Level: District		2
	System Level: Health facility		62
	Commodity: Condoms		62
	Commodity: ARV drugs		408
	Commodity: Rapid test kits		235
	Commodity: OI drugs		235
	Commodity: Other		408



Partners and Implementing Mechanisms

Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
7500	Program for Appropriate Technology in Health	NGO	U.S. Agency for International Development	GHP-State, GHP-USAID	4,400,000
10612	Kinshasa School of Public Health	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GAP	0
11054	Population Services International	NGO	U.S. Department of Defense	GHP-State	2,420,000
13010	Management Sciences for Health	NGO	U.S. Agency for International Development	GHP-State, GHP-USAID	1,513,500
13017	American Society for Microbiology	Private Contractor	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	150,000
13094	Association of Public Health Laboratories	NGO	U.S. Department of Health and Human Services/Centers	GHP-State	200,000



			for Disease Control and Prevention		
13183	Programme National de Lutte contre le VIH/SIDA et IST	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	250,000
13338	Tulane University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13476	International Center for AIDS Care and Treatment Programs, Columbia University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	8,530,794
13542	Programme National de Transfusion et Sécurité Sanguine	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	300,000
13595	FHI 360	NGO	U.S. Agency for International Development	GHP-State, GHP-USAID	2,370,245
13623	FHI 360	NGO	U.S. Department of Health and	GHP-State	1,000,000



			Human Services/Centers for Disease Control and Prevention		
13696	Partnership for Supply Chain Management	Private Contractor	U.S. Agency for International Development	GHP-State, GHP-USAID	8,883,301
13703	Management Sciences for Health	NGO	U.S. Agency for International Development	GHP-State, GHP-USAID	650,000
13730	Elizabeth Glaser Pediatric AIDS Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	3,774,160
14611	Program for Appropriate Technology in Health	NGO	U.S. Agency for International Development	GHP-State	0
14612	World Health Organization	Multi-lateral Agency	U.S. Agency for International Development	GHP-State	250,000
14809	FHI 360	NGO	U.S. Agency for International Development	GHP-State, GHP-USAID	1,020,000
14831	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	268,000
16934	VOICE OF AMERICA	NGO	U.S. Department of State/Bureau of African Affairs	GHP-State	192,000
16963	Elizabeth Glaser	NGO	U.S. Department	GHP-State	5,250,000



	Pediatric AIDS Foundation		of Health and Human Services/Centers for Disease Control and Prevention		
16997	IntraHealth International, Inc	NGO	U.S. Agency for International Development	GHP-State	0
17176	University Research Corporation, LLC	Private Contractor	U.S. Agency for International Development	GHP-USAID	428,000
17177	SANRU	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,550,000
17179	TBD	TBD	Redacted	Redacted	Redacted
17609	TBD	TBD	Redacted	Redacted	Redacted
17611	TBD	TBD	Redacted	Redacted	Redacted
17612	TBD	TBD	Redacted	Redacted	Redacted
17614	TBD	TBD	Redacted	Redacted	Redacted
17627	TBD	TBD	Redacted	Redacted	Redacted
17628	TBD	TBD	Redacted	Redacted	Redacted
17630	TBD	TBD	Redacted	Redacted	Redacted
17631	TBD	TBD	Redacted	Redacted	Redacted
17633	FHI 360	NGO	U.S. Agency for International Development	GHP-USAID	550,000
17636	Population Services International	NGO	U.S. Agency for International Development	GHP-State	750,000

Approved



17637	FHI 360	NGO	U.S. Agency for International Development	GHP-USAID, GHP-State	550,000
17639	TBD	TBD	Redacted	Redacted	Redacted



Implementing Mechanism(s)

Implementing Mechanism Details

Mechanism ID: 17639	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17637	Mechanism Name: FANTA
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 550,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	109,755
GHP-USAID	440,245

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Food and Nutrition: Policy, Tools, and Service Delivery	550,000
---	---------



Key Issues

Child Survival Activities

TB

Budget Code Information

Mechanism ID: 17637			
Mechanism Name: FANTA			
Prime Partner Name: FHI 360			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	550,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	16	36
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	0	0



SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	16	36
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: VMMC Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: PHDP/Family	0	0



	Planning & Integration Technical Assistance-only (TA)		
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	0	0

Implementing Mechanism Details

Mechanism ID: 17636	Mechanism Name: SIFPO
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Population Services International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 750,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	750,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Key Populations: FSW	300,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Monitoring and evaluation of SW programs



Condom programming	400,000
Key Populations: MSM and TG	150,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Monitoring and evaluation of MSM/TG programs

Key Issues

Child Survival Activities

Family Planning

Budget Code Information

Mechanism ID: 17636			
Mechanism Name: SIFPO			
Prime Partner Name: Population Services International			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	650,000	0

Implementing Mechanism Indicator Information

Approved



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17633	Mechanism Name: Livelihoods and Food Security Technical Assistance (LIFT) II
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 550,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-USAID	550,000

Sub Partner Name(s)

Care International		
--------------------	--	--

Cross-Cutting Budget Attribution(s)

Economic Strengthening	125,000
------------------------	---------

Key Issues

Malaria (PMI)
Child Survival Activities
Military Population
Mobile Population

Approved



Safe Motherhood
Workplace Programs
End-of-Program Evaluation
Family Planning

Budget Code Information

Mechanism ID: 17633			
Mechanism Name: Livelihoods and Food Security Technical Assistance (LIFT) II			
Prime Partner Name: FHI 360			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	550,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17631	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17630	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17628	TBD: Yes
REDACTED	



Implementing Mechanism Details

Mechanism ID: 17627	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17614	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17612	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17611	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17609	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17179	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17177	Mechanism Name: SANRU Clinical and PMTCT
---------------------	--

Approved



	Scale-up
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: SANRU	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: PR/SR	
G2G: No	Managing Agency:

Total All Funding Sources: 1,550,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	1,550,000

Sub Partner Name(s)

Interchurch Medical Assistance		
--------------------------------	--	--

Cross-Cutting Budget Attribution(s)

Human Resources for Health	150,000
Motor Vehicles: Purchased	60,000
Motor Vehicles: Leased	39,600

Key Issues

Child Survival Activities
Mobile Population
Safe Motherhood
TB
Family Planning



Budget Code Information

Mechanism ID: 17177			
Mechanism Name: SANRU Clinical and PMTCT Scale-up			
Prime Partner Name: SANRU			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	151,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	42,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	210,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	84,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	42,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	802,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	176,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	42,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget
------------------	-------	------	------	-----------------



				Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	175	350	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	25	50	Redacted
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	25	50	Redacted
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	25	50	Redacted
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	25	50	Redacted
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	25	50	Redacted
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: General	0	0	Redacted



	Population Prevention Direct Service Delivery (DSD)			
SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	25	50	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	25	50	Redacted
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	0	0	Redacted
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	35	356	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	50	499	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	35	351	Redacted

PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	33	329	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	2	22	Redacted
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	5	Redacted
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	35	356	Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	35	351	Redacted
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	35		Redacted
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	50		Redacted
PMTCT_ARV_NGI	Life-long ART (including Option B+)	35		Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	33		Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	2		Redacted
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with the intention to stop at	0		Redacted



	the end of the breastfeeding period)			
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0		Redacted
PMTCT_ARV_NGI	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_NGI	Sum of Regimen disaggregates	35		Redacted
PMTCT_ARV_NGI	Sum of New and Current disaggregates	35		Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,619	16,190	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	2,314	23,140	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	3	30	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	47	469	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	50	499	Redacted
PMTCT_STAT_NG I	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,619		Redacted
PMTCT_STAT_NG I	Number of new ANC and L&D clients	2,314		Redacted
PMTCT_STAT_NG I	By: Known positives at entry	3		Redacted
PMTCT_STAT_NG I	By: Number of new positives identified	47		Redacted
PMTCT_STAT_NG I	Sum of Positives Status disaggregates	50		Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their	1,830	18,400	Redacted

	test results during the past 12 months			
HTC_TST_DSD	By Test Result: Negative	1,775	17,853	Redacted
HTC_TST_DSD	By Test Result: Positive	55	547	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	1,830	18,400	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	46		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	89		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	46		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,649		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	92		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	1,738		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	1,830		Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,830	18,400	Redacted
HTC_TST_NGI	By Test Result: Negative	1,775	17,853	Redacted
HTC_TST_NGI	By Test Result: Positive	55	547	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	1,830	18,400	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	46		Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	89		Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	46		Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	1,649		Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	92		Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	1,738		Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	1,830		Redacted
GEND_GBV_DSD	Number of people receiving post-GBV care	2	20	Redacted
C2.1.D_DSD	Number of HIV-positive individuals	85		Redacted



	receiving a minimum of one clinical service			
C2.1.D_DSD	By Age/Sex: <15 Female	21		Redacted
C2.1.D_DSD	By Age/Sex: <15 Male	21		Redacted
C2.1.D_DSD	By Age/Sex: 15+ Female	41		Redacted
C2.1.D_DSD	By Age/Sex: 15+ Male	2		Redacted
C2.1.D_DSD	Sum of Age/Sex disaggregates	85		Redacted
C2.1.D_DSD	By Age: <15	42		Redacted
C2.1.D_DSD	By Age: 15+	43		Redacted
C2.1.D_DSD	Sum of Age disaggregates	85		Redacted
C2.1.D_DSD	By Sex: Female	62		Redacted
C2.1.D_DSD	By Sex: Male	23		Redacted
C2.1.D_DSD	Sum of Sex disaggregates	85		Redacted
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	85		Redacted
C2.1.D_NGI	By Age/Sex: <15 Female	21		Redacted
C2.1.D_NGI	By Age/Sex: <15 Male	21		Redacted
C2.1.D_NGI	By Age/Sex: 15+ Female	41		Redacted
C2.1.D_NGI	By Age/Sex: 15+ Male	2		Redacted
C2.1.D_NGI	Sum of Age/Sex disaggregates	85		Redacted
C2.1.D_NGI	By Age: <15	42		Redacted
C2.1.D_NGI	By Age: 15+	43		Redacted
C2.1.D_NGI	Sum of Age disaggregates	85		Redacted
C2.1.D_NGI	By Sex: Female	62		Redacted
C2.1.D_NGI	By Sex: Male	23		Redacted
C2.1.D_NGI	Sum of Sex disaggregates	85		Redacted
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	85		Redacted
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	85		Redacted

CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	85	1,054	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	21		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	2		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	21		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	41		Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	85		Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	25	248	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	50	499	Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	20	199	Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	5	49	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	25	248	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	1	2	Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	85	1,054	Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	27	50	Redacted

TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	73	71	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	21		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	21		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	21		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	2		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	21		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	41		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	42		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	43		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	85		Redacted
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	85	1,054	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	21		Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	21		Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	21		Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	2		Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	21		Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	41		Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	85		Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	42		Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	43		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	85	969	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	0		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	0		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	2		Redacted

TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	21		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	21		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	41		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	64		Redacted
TX_NEW_DSD	Pregnancy status	5	15	Redacted
TX_NEW_DSD	Breastfeeding status	3	10	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	0	67	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	0	85	Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0		Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator:	0		Redacted



	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)			
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	25	50	Redacted
LAB_CAP_DSD	By clinical laboratories	5	5	Redacted
LAB_CAP_DSD	By Point-of-care testing sites	20	45	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	25	50	Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	0	0	Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	25	50	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	85	1,054	Redacted

Implementing Mechanism Details



Mechanism ID: 17176	Mechanism Name: Applying Science to Strengthen and Improve Systems (ASSIST)
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: University Research Corporation, LLC	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:
Total All Funding Sources: 428,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-USAID	428,000

Sub Partner Name(s)

Broad Branch Associates	EnCompass LLC	FHI 360
Harvard University School of Public Health	Health Research Inc./New York AIDS Institute	Institute for Healthcare Improvement (IHI)
Johns Hopkins University Center for Communication Programs	TBD	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

Child Survival Activities

Safe Motherhood



Budget Code Information

Mechanism ID:	17176		
Mechanism Name:	Applying Science to Strengthen and Improve Systems (ASSIST)		
Prime Partner Name:	University Research Corporation, LLC		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	250,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	178,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	10	50
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	10	50
SITE_SUPP	By program area/support type: PMTCT Direct	0	0



	Service Delivery (DSD)		
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	0	0

Implementing Mechanism Details



Mechanism ID: 16997	Mechanism Name: Capacity Plus
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: IntraHealth International, Inc	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

Abt Associates	IMA World Health	Liverpool Associates in Tropical Health
Training Resources Group		

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	16997
Mechanism Name:	Capacity Plus
Prime Partner Name:	IntraHealth International, Inc



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16963	Mechanism Name: Increase Access to Comprehensive HIV/AIDS Prevention Care and Treatment Services in the Democratic Republic of Congo under (PEPFAR) (KIMIA)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:
Total All Funding Sources: 5,250,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	5,250,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Gender: GBV	150,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic



	Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Motor Vehicles: Purchased	58,000
Renovation	120,000

Key Issues

- Child Survival Activities
- Safe Motherhood
- TB
- Family Planning

Budget Code Information

Mechanism ID:	16963		
Mechanism Name:	Increase Access to Comprehensive HIV/AIDS Prevention Care and Treatment Services in the Democratic Republic of Congo under		
Prime Partner Name:	(PEPFAR) (KIMIA) Elizabeth Glaser Pediatric AIDS Foundation		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	1,062,542	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HKID	88,806	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	807,894	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	544,360	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	58,700	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	29,350	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	58,700	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	72,905	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	1,461,318	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	867,325	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	198,100	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning
------------------	-------	------	------	----------



				Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	911	1,339	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	136	176	Redacted
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	136	176	Redacted
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	136	176	Redacted
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	0	176	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	95	107	Redacted
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	136	176	Redacted
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	0	0	Redacted

SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	136	176	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	136	176	Redacted
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	0	0	Redacted
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	1,539	1,987	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	1,620	2,092	Redacted
PMTCT_ARV_DS	Life-long ART (including Option B+)	846	1,987	Redacted



D				
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	296	696	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	550	1,291	Redacted
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	693	0	Redacted
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	1,539	1,987	Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	846	1,987	Redacted
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	1,539		Redacted
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	1,620		Redacted
PMTCT_ARV_NGI	Life-long ART (including Option B+)	846		Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	296		Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	550		Redacted
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis	0		Redacted

	(provided with the intention to stop at the end of the breastfeeding period)			
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	693		Redacted
PMTCT_ARV_NGI	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_NGI	Sum of Regimen disaggregates	1,539		Redacted
PMTCT_ARV_NGI	Sum of New and Current disaggregates	846		Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	90,000	116,843	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	95,745	121,711	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	389	502	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	1,231	1,590	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	1,620	2,092	Redacted
PMTCT_STAT_NG I	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	90,000	90,000	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	120,914	154,484	Redacted
HTC_TST_DSD	By Test Result: Negative	116,319	148,141	Redacted
HTC_TST_DSD	By Test Result: Positive	4,595	6,343	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	120,914	154,484	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,244		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ	21,366		Redacted



	PERMISSION ONLY: 15+ Male			
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,488		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	96,816		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	2,732		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	118,182		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	120,914		Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	120,914	154,484	Redacted
HTC_TST_NGI	By Test Result: Negative	116,319	148,141	Redacted
HTC_TST_NGI	By Test Result: Positive	4,595	6,343	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	120,914	154,484	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	1,244		Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	21,366		Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	1,488		Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	96,816		Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	2,732		Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	118,182		Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	120,914		Redacted
GEND_GBV_DSD	Number of people receiving post-GBV care	36	48	Redacted
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	4,729		Redacted
C2.1.D_DSD	By Age/Sex: <15 Female	1,166		Redacted
C2.1.D_DSD	By Age/Sex: <15 Male	1,127		Redacted
C2.1.D_DSD	By Age/Sex: 15+ Female	1,866		Redacted
C2.1.D_DSD	By Age/Sex: 15+ Male	570		Redacted
C2.1.D_DSD	Sum of Age/Sex disaggregates	4,729		Redacted



C2.1.D_DSD	By Age: <15	2,293		Redacted
C2.1.D_DSD	By Age: 15+	2,436		Redacted
C2.1.D_DSD	Sum of Age disaggregates	4,729		Redacted
C2.1.D_DSD	By Sex: Female	3,032		Redacted
C2.1.D_DSD	By Sex: Male	1,697		Redacted
C2.1.D_DSD	Sum of Sex disaggregates	4,729		Redacted
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	4,729		Redacted
C2.1.D_NGI	By Age/Sex: <15 Female	1,166		Redacted
C2.1.D_NGI	By Age/Sex: <15 Male	1,127		Redacted
C2.1.D_NGI	By Age/Sex: 15+ Female	1,866		Redacted
C2.1.D_NGI	By Age/Sex: 15+ Male	570		Redacted
C2.1.D_NGI	Sum of Age/Sex disaggregates	4,729		Redacted
C2.1.D_NGI	By Age: <15	2,293		Redacted
C2.1.D_NGI	By Age: 15+	2,436		Redacted
C2.1.D_NGI	Sum of Age disaggregates	4,729		Redacted
C2.1.D_NGI	By Sex: Female	3,032		Redacted
C2.1.D_NGI	By Sex: Male	1,697		Redacted
C2.1.D_NGI	Sum of Sex disaggregates	4,729		Redacted
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	4,066		Redacted
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	4,729		Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	3,205	11,400	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	123		Redacted

CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	2,082		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	492		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	7,552		Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	10,249		Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	0	321	Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	0	338	Redacted
FN_THER_DSD	Aggregated Age: <18	0		Redacted
FN_THER_DSD	Aggregated Age: 18+	0		Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	0		Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	389	727	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	1,620	2,092	Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	354	662	Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	35	65	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	389	727	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	19	52	Redacted
TX_CURR_DSD	Number of adults and children receiving	4,729	10,863	Redacted

	antiretroviral therapy (ART)			
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	36	49	Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	64	64	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	6		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	6		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,127		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	570		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,166		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	1,866		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	2,293		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	2,436		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	4,729		Redacted
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	4,729	8,345	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	6		Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	6		Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	1,127		Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	570		Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	1,166		Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	1,866		Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	4,729		Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	2,293		Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	2,436		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,722	6,134	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	14		Redacted



TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	640		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	341		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	14		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	690		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	1,051		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	2,722		Redacted
TX_NEW_DSD	Pregnancy status	635	2,242	Redacted
TX_NEW_DSD	Breastfeeding status	211	747	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	3,801	7,093	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	4,751	8,345	Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,837		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,964		Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting	2,296		Redacted

	period, including those who have died, those who have stopped ART, and those lost to follow-up)			
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,455		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	923		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,539		Redacted
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	0	2	Redacted
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	0	2	Redacted
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	0	0	Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	0	2	Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing	136	177	Redacted



	facilities with capacity to perform clinical laboratory tests			
LAB_CAP_DSD	By clinical laboratories	4	5	Redacted
LAB_CAP_DSD	By Point-of-care testing sites	132	172	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	136	177	Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	0	0	Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	136	177	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	3,205	11,400	Redacted

Implementing Mechanism Details

Mechanism ID: 16934	Mechanism Name: Voice of America: Votre Sante, Votre Avenir
Funding Agency: State/AF	Procurement Type: Grant
Prime Partner Name: VOICE OF AMERICA	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 192,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	192,000

Sub Partner Name(s)

(No data provided.)



Cross-Cutting Budget Attribution(s)

Gender: GBV	15,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Key Populations: MSM and TG	10,000
Focus Area:	Collection and use of strategic information

Key Issues

- Military Population
- Mobile Population
- Safe Motherhood
- TB
- Family Planning

Budget Code Information

Mechanism ID:	16934		
Mechanism Name:	Voice of America: Votre Sante, Votre Avenir		
Prime Partner Name:	VOICE OF AMERICA		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	10,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HVOP	40,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	142,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14831	Mechanism Name: Small Grant Program
Funding Agency: State/AF	Procurement Type: Inter-Agency Agreement
Prime Partner Name: U.S. Department of State	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 268,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	268,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Gender: GBV	25,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information



Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Key Populations: MSM and TG	15,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information
Key Populations: FSW	15,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients

Key Issues

- Military Population
- Mobile Population
- Safe Motherhood
- TB
- Family Planning

Budget Code Information

Mechanism ID: 14831			
Mechanism Name: Small Grant Program			
Prime Partner Name: U.S. Department of State			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	40,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	160,000	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	68,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14809	Mechanism Name: C-Change/DRC – Social and Behavior Change Communication (SBCC) Capacity Building in the Democratic Republic of Congo / USAID Leader with Associates Cooperative Agreement No. GPO-A-00-07-00004-00
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 1,020,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	1,020,000
GHP-USAID	0

Sub Partner Name(s)

Search for Common Ground		
--------------------------	--	--



Cross-Cutting Budget Attribution(s)

Gender: GBV	450,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Gender: Gender Equality	250,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Key Populations: MSM and TG	125,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Key Populations: FSW	75,000



Focus Area:	Training of health workers and community outreach workers
-------------	---

Key Issues

- Malaria (PMI)
- Child Survival Activities
- TB
- Family Planning

Budget Code Information

Mechanism ID:	14809		
Mechanism Name:	C-Change/DRC – Social and Behavior Change Communication (SBCC)		
Prime Partner Name:	Capacity Building in the Democratic Republic of Congo / USAID Leader with Associates Cooperative Agreement No. GPO-A-00-07-00004-00		
	FHI 360		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	170,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	350,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	300,000	0

Implementing Mechanism Indicator Information



Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	43	54
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	42	52
SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	0	0



SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	1	2
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	0	0
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	9,905	12,381
PP_PREV_DSD	Total number of people in the target population	39,012	40,182
PP_PREV_DSD	Age/sex: 10-14 Male	1,972	2,465
PP_PREV_DSD	Age/sex: 15-19 Male	1,440	1,800
PP_PREV_DSD	Age/sex: 20-24 Male	1,440	1,800
PP_PREV_DSD	Age/sex: 25-49 Male	0	0
PP_PREV_DSD	Age/sex: 50+ Male	0	0
PP_PREV_DSD	Age/sex: 10-14 Female	2,053	2,566
PP_PREV_DSD	Age/sex: 15-19 Female	1,500	1,875
PP_PREV_DSD	Age/sex: 20-24 Female	1,500	1,875



PP_PREV_DSD	Age/sex: 25-49 Female	0	0
PP_PREV_DSD	Age/sex: 50+ Female	0	0
PP_PREV_DSD	Sum of Age/Sex disaggregates	9,905	12,381
KP_PREV_TA	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	478	1,384
KP_PREV_TA	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	478	1,048
KP_PREV_TA	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0
KP_PREV_TA	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0
KP_PREV_TA	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	179
KP_PREV_TA	By key population type: MSM/TG who are male sex workers (subset MSM/TG)	0	157



	(Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)		
--	--	--	--

Implementing Mechanism Details

Mechanism ID: 14612	Mechanism Name: Health Zone Strengthening Award
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: World Health Organization	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 250,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	250,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	200,000
----------------------------	---------

Key Issues

(No data provided.)



Budget Code Information

Mechanism ID: 14612			
Mechanism Name: Health Zone Strengthening Award			
Prime Partner Name: World Health Organization			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	250,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14611	Mechanism Name: Projet du SIDA Fungurume (ProSIFU)
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: Program for Appropriate Technology in Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

Chemonics International		
-------------------------	--	--



Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

- Child Survival Activities
- Mobile Population
- Safe Motherhood
- TB
- Workplace Programs
- Family Planning

Budget Code Information

Mechanism ID: 14611			
Mechanism Name: Projet du SIDA Fungurume (ProSIFU)			
Prime Partner Name: Program for Appropriate Technology in Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0



Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	92	
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	7	
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	0	
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	7	
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	0	
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	7	
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	0	
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	7	
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	0	
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	7	
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	0	
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	7	
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	0	
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	12	
SITE_SUPP	By program area/support type: General	0	



	Population Prevention Technical Assistance-only (TA)		
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	12	
SITE_SUPP	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	0	
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	12	
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	0	
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	7	
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	0	
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	7	
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	0	
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	59	
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	63	
PMTCT_ARV_DSD	Life-long ART (including Option B+)	24	
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	15	
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	9	



PMTCT_ARV_DSD	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	
PMTCT_ARV_DSD	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	35	
PMTCT_ARV_DSD	Single-dose nevirapine (with or without tail)	0	
PMTCT_ARV_DSD	Sum of Regimen Type disaggregates	59	
PMTCT_ARV_DSD	Sum of New and Current disaggregates	24	
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	59	
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	63	
PMTCT_ARV_NGI	Life-long ART (including Option B+)	24	
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	15	
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	9	
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	35	
PMTCT_ARV_NGI	Single-dose nevirapine (with or without tail)	0	
PMTCT_ARV_NGI	Sum of Regimen disaggregates	59	
PMTCT_ARV_NGI	Sum of New and Current disaggregates	24	
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	2,961	



PMTCT_STAT_DSD	Number of new ANC and L&D clients	3,003	
PMTCT_STAT_DSD	By: Known positives at entry	9	
PMTCT_STAT_DSD	By: Number of new positives identified	54	
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	63	
PMTCT_STAT_NGI	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	2,961	
PMTCT_STAT_NGI	Number of new ANC and L&D clients	3,003	
PMTCT_STAT_NGI	By: Known positives at entry	9	
PMTCT_STAT_NGI	By: Number of new positives identified	54	
PMTCT_STAT_NGI	Sum of Positives Status disaggregates	63	
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	19,791	
PP_PREV_DSD	Total number of people in the target population	36,458	
PP_PREV_DSD	Age/sex: 10-14 Male	1,224	
PP_PREV_DSD	Age/sex: 15-19 Male	1,282	
PP_PREV_DSD	Age/sex: 20-24 Male	1,419	
PP_PREV_DSD	Age/sex: 25-49 Male	4,102	
PP_PREV_DSD	Age/sex: 50+ Male	171	
PP_PREV_DSD	Age/sex: 10-14 Female	1,358	
PP_PREV_DSD	Age/sex: 15-19 Female	1,410	
PP_PREV_DSD	Age/sex: 20-24 Female	2,888	
PP_PREV_DSD	Age/sex: 25-49 Female	5,728	
PP_PREV_DSD	Age/sex: 50+ Female	209	
PP_PREV_DSD	Sum of Age/Sex disaggregates	19,791	
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	1,296	



KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,296	
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	
KP_PREV_DSD	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	4,873	
HTC_TST_DSD	By Test Result: Negative	4,629	



HTC_TST_DSD	By Test Result: Positive	244	
HTC_TST_DSD	Sum of Test Result disaggregates	4,873	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	352	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	846	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	526	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	3,149	
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	878	
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	3,995	
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	4,873	
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	4,873	
HTC_TST_NGI	By Test Result: Negative	4,629	
HTC_TST_NGI	By Test Result: Positive	244	
HTC_TST_NGI	Sum of Test Result disaggregates	4,873	
HTC_TST_NGI	Aggregated Age/sex: <15 Male	352	
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	846	
HTC_TST_NGI	Aggregated Age/sex: <15 Female	526	
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	3,149	
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	878	
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	3,995	
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	4,873	
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	125	
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	399	
C2.1.D_DSD	By Age/Sex: <15 Female	14	
C2.1.D_DSD	By Age/Sex: <15 Male	10	



C2.1.D_DSD	By Age/Sex: 15+ Female	225	
C2.1.D_DSD	By Age/Sex: 15+ Male	150	
C2.1.D_DSD	Sum of Age/Sex disaggregates	399	
C2.1.D_DSD	By Age: <15	24	
C2.1.D_DSD	By Age: 15+	375	
C2.1.D_DSD	Sum of Age disaggregates	399	
C2.1.D_DSD	By Sex: Female	235	
C2.1.D_DSD	By Sex: Male	164	
C2.1.D_DSD	Sum of Sex disaggregates	399	
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	399	
C2.1.D_NGI	By Age/Sex: <15 Female	14	
C2.1.D_NGI	By Age/Sex: <15 Male	10	
C2.1.D_NGI	By Age/Sex: 15+ Female	225	
C2.1.D_NGI	By Age/Sex: 15+ Male	150	
C2.1.D_NGI	Sum of Age/Sex disaggregates	399	
C2.1.D_NGI	By Age: <15	24	
C2.1.D_NGI	By Age: 15+	375	
C2.1.D_NGI	Sum of Age disaggregates	399	
C2.1.D_NGI	By Sex: Female	235	
C2.1.D_NGI	By Sex: Male	164	
C2.1.D_NGI	Sum of Sex disaggregates	399	
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	370	
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	399	
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	399	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ	10	



	PERMISSION ONLY: <15 Male		
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	150	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	14	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	225	
CARE_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	399	
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	14	
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	63	
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	12	
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	2	
PMTCT_EID_DSD	Sum of Infant Age disaggregates	14	
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	2	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	201	
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	0	
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	0	
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	2	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	67	
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	2	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	130	
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	4	
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	197	
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	201	



TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	201	
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	0	
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	0	
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	2	
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	67	
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	2	
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	130	
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	201	
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	4	
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	197	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	201	
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	1	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	2	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	67	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	1	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	2	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	130	
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	201	
TX_NEW_DSD	Pregnancy status	15	
TX_NEW_DSD	Breastfeeding status	28	
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	7	
LAB_CAP_DSD	By clinical laboratories	0	
LAB_CAP_DSD	By Point-of-care testing sites	7	
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	7	
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	0	



LAB_CAP_DSD	Sum of Site Support Type disaggregates	7	
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	399	

Implementing Mechanism Details

Mechanism ID: 13730	Mechanism Name: Malamu
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 3,774,160	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	3,774,160

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

Child Survival Activities

Safe Motherhood

TB

Custom



Family Planning

Budget Code Information

Mechanism ID: 13730			
Mechanism Name: Malamu			
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	683,491	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	62,482	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	598,059	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	433,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	41,300	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	20,650	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	41,300	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	51,295	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	MTCT	1,063,330	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	539,873	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	239,380	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	909	909	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	101	101	Redacted
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	101	101	Redacted
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	101	101	Redacted
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery	101	101	Redacted



	(DSD)			
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	101	101	Redacted
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	101	101	Redacted
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	101	101	Redacted
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	101	101	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	0	0	Redacted

SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	101	101	Redacted
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	0	0	Redacted
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	898	1,111	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	998	1,170	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	494	1,111	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	282	477	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	212	634	Redacted
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	404	0	Redacted
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	898	1,111	Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	494	1,111	Redacted
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of	898		Redacted



	mother-to-child-transmission (MTCT) during pregnancy and delivery			
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	998		Redacted
PMTCT_ARV_NGI	Life-long ART (including Option B+)	494		Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	282		Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	212		Redacted
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	404		Redacted
PMTCT_ARV_NGI	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_NGI	Sum of Regimen disaggregates	898		Redacted
PMTCT_ARV_NGI	Sum of New and Current disaggregates	494		Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	45,350	53,157	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	47,240	55,372	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	70	82	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	928	1,088	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	998	1,170	Redacted



PMTCT_STAT_NG I	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	45,350		Redacted
PMTCT_STAT_NG I	Number of new ANC and L&D clients	47,240		Redacted
PMTCT_STAT_NG I	By: Known positives at entry	70		Redacted
PMTCT_STAT_NG I	By: Number of new positives identified	928		Redacted
PMTCT_STAT_NG I	Sum of Positives Status disaggregates	998		Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	60,303	86,896	Redacted
HTC_TST_DSD	By Test Result: Negative	58,554	77,878	Redacted
HTC_TST_DSD	By Test Result: Positive	1,749	2,413	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	60,303	80,291	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	121		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	4,945		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	362		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	54,875		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	483		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	59,820		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	60,303		Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	60,303	86,896	Redacted
HTC_TST_NGI	By Test Result: Negative	58,554	77,878	Redacted



HTC_TST_NGI	By Test Result: Positive	1,749	2,413	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	60,303	80,291	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	121		Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	4,945		Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	362		Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	54,875		Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	483		Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	59,820		Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	60,303		Redacted
GEND_GBV_DSD	Number of people receiving post-GBV care	32	27	Redacted
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	3,446		Redacted
C2.1.D_DSD	By Age/Sex: <15 Female	857		Redacted
C2.1.D_DSD	By Age/Sex: <15 Male	817		Redacted
C2.1.D_DSD	By Age/Sex: 15+ Female	1,350		Redacted
C2.1.D_DSD	By Age/Sex: 15+ Male	422		Redacted
C2.1.D_DSD	Sum of Age/Sex disaggregates	3,446		Redacted
C2.1.D_DSD	By Age: <15	1,674		Redacted
C2.1.D_DSD	By Age: 15+	1,772		Redacted
C2.1.D_DSD	Sum of Age disaggregates	3,446		Redacted
C2.1.D_DSD	By Sex: Female	2,207		Redacted
C2.1.D_DSD	By Sex: Male	1,239		Redacted
C2.1.D_DSD	Sum of Sex disaggregates	3,446		Redacted
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	3,446		Redacted
C2.1.D_NGI	By Age/Sex: <15 Female	857		Redacted
C2.1.D_NGI	By Age/Sex: <15 Male	817		Redacted
C2.1.D_NGI	By Age/Sex: 15+ Female	1,350		Redacted
C2.1.D_NGI	By Age/Sex: 15+ Male	422		Redacted

C2.1.D_NGI	Sum of Age/Sex disaggregates	3,446		Redacted
C2.1.D_NGI	By Age: <15	588		Redacted
C2.1.D_NGI	By Age: 15+	1,052		Redacted
C2.1.D_NGI	Sum of Age disaggregates	1,640		Redacted
C2.1.D_NGI	By Sex: Female	1,155		Redacted
C2.1.D_NGI	By Sex: Male	485		Redacted
C2.1.D_NGI	Sum of Sex disaggregates	1,640		Redacted
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	2,757		Redacted
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	3,446		Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	2,675	6,408	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	32		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	550		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	128		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,965		Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	2,675		Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	0	209	Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be	0	220	Redacted

	clinically undernourished.			
FN_THER_DSD	Aggregated Age: <18	0		Redacted
FN_THER_DSD	Aggregated Age: 18+	0		Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	0		Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	359	410	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	998	1,170	Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	327	373	Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	32	37	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	359	410	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	18	6	Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	3,446	6,898	Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	36		Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	64		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	7		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	9		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	817		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	422		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	857		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	1,350		Redacted



TX_CURR_DSD	Sum of Aggregated Age/Sex <15	1,674		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	1,772		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	3,446		Redacted
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	3,446	4,696	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	7		Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	9		Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	817		Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	422		Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	857		Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	1,350		Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	3,446		Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	1,674		Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	1,772		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,236	3,452	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	5		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	298		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	155		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	6		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	312		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	471		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,236		Redacted
TX_NEW_DSD	Pregnancy status	211	807	Redacted
TX_NEW_DSD	Breastfeeding status	71	269	Redacted



TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,581	3,990	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	3,439	4,694	Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,248		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,333		Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,662		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,777		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	140		Redacted



TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	234		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	101	101	Redacted
LAB_CAP_DSD	By clinical laboratories	2	2	Redacted
LAB_CAP_DSD	By Point-of-care testing sites	99	99	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	101	101	Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	0	0	Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	101	101	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	2,675	6,408	Redacted

Implementing Mechanism Details

Mechanism ID: 13703	Mechanism Name: Systems for Improved Access to Pharmaceuticals and Services (SIAPS)
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: Management Sciences for Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Approved



Total All Funding Sources: 650,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	500,000
GHP-USAID	150,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 13703			
Mechanism Name: Systems for Improved Access to Pharmaceuticals and Services (SIAPS)			
Prime Partner Name: Management Sciences for Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	325,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	325,000	0

Implementing Mechanism Indicator Information



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13696	Mechanism Name: Supply Chain Management System
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: Partnership for Supply Chain Management	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 8,883,301	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	5,000,000
GHP-USAID	3,883,301

Sub Partner Name(s)

3i Infocepts	Booz Allen Hamilton	Crown Agents
i+solutions	Imperial Health Sciences	John Snow Inc (JSI)
Management Sciences for Health	Northrup Grumman	The Manoff Group
UPS	Voxiva	

Cross-Cutting Budget Attribution(s)

Human Resources for Health	300,000
Gender: GBV	170,000
Focus Area:	Post GBV Care
Sub Area:	Implementation



Sub Area:	Monitoring and Evaluation
-----------	---------------------------

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 13696			
Mechanism Name: Supply Chain Management System			
Prime Partner Name: Partnership for Supply Chain Management			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	1,100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	850,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	625,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	350,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	600,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	350,000	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXD	3,183,301	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,225,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	500,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13623	Mechanism Name: Providing Capacity-Building Assistance to Government and Indigenous Congolese Organizations to Improve HIV/AIDS Service Delivery in the Democratic Republic of Congo under PEPFAR
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:
Total All Funding Sources: 1,000,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	1,000,000

Sub Partner Name(s)

Approved



(No data provided.)

Cross-Cutting Budget Attribution(s)

Motor Vehicles: Purchased	45,000
---------------------------	--------

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 13623 Mechanism Name: Providing Capacity-Building Assistance to Government and Indigenous Congolese Organizations to Improve HIV/AIDS Service Delivery in the Prime Partner Name: Democratic Republic of Congo under PEPFAR FHI 360			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	700,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	300,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13595	Mechanism Name: ROADS II
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: FHI 360	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 2,370,245	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	1,570,245
GHP-USAID	800,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	150,000
Key Populations: FSW	50,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs
Key Populations: MSM and TG	10,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions



	for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for MSM/TG
Economic Strengthening	45,000
Gender: GBV	40,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	10,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation



Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

Key Issues

Mobile Population

TB

Budget Code Information

Mechanism ID: 13595			
Mechanism Name: ROADS II			
Prime Partner Name: FHI 360			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	859,917	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	HVSI	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	186,162	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	574,194	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	599,972	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	40	50
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	8	10
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	8	10
SITE_SUPP	By program area/support type: Care and	0	0



	Support Direct Service Delivery (DSD)		
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	8	10
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	8	10
SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	8	10
SITE_SUPP	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	0	0



SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	0	0
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	45,000	57,500
PP_PREV_DSD	Total number of people in the target population	136,962	204,962
PP_PREV_DSD	Age/sex: 10-14 Male	2,206	2,817
PP_PREV_DSD	Age/sex: 15-19 Male	5,512	7,044
PP_PREV_DSD	Age/sex: 20-24 Male	5,512	7,044
PP_PREV_DSD	Age/sex: 25-49 Male	6,614	8,453
PP_PREV_DSD	Age/sex: 50+ Male	2,206	2,817
PP_PREV_DSD	Age/sex: 10-14 Female	2,294	2,933
PP_PREV_DSD	Age/sex: 15-19 Female	5,738	7,331
PP_PREV_DSD	Age/sex: 20-24 Female	5,738	7,331
PP_PREV_DSD	Age/sex: 25-49 Female	6,886	8,797
PP_PREV_DSD	Age/sex: 50+ Female	2,294	2,933
PP_PREV_DSD	Sum of Age/Sex disaggregates	45,000	57,500
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	2,000	6,000
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the	2,000	6,000



	minimum standards required)		
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0
KP_PREV_DSD	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	7,000	20,000
HTC_TST_DSD	By Test Result: Negative	6,580	18,800
HTC_TST_DSD	By Test Result: Positive	420	1,200
HTC_TST_DSD	Sum of Test Result disaggregates	7,000	20,000
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0	



HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	3,430	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	3,570	
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	0	
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	7,000	
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	7,000	
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	7,000	20,000
HTC_TST_NGI	By Test Result: Negative	6,580	18,800
HTC_TST_NGI	By Test Result: Positive	420	1,200
HTC_TST_NGI	Sum of Test Result disaggregates	7,000	20,000
HTC_TST_NGI	Aggregated Age/sex: <15 Male	0	
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	3,430	
HTC_TST_NGI	Aggregated Age/sex: <15 Female	0	
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	3,570	
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	0	
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	7,000	
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	7,000	
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	300	
C2.1.D_DSD	By Age/Sex: <15 Female	0	
C2.1.D_DSD	By Age/Sex: <15 Male	0	
C2.1.D_DSD	By Age/Sex: 15+ Female	153	
C2.1.D_DSD	By Age/Sex: 15+ Male	147	
C2.1.D_DSD	Sum of Age/Sex disaggregates	300	
C2.1.D_DSD	By Age: <15	0	
C2.1.D_DSD	By Age: 15+	300	
C2.1.D_DSD	Sum of Age disaggregates	300	
C2.1.D_DSD	By Sex: Female	153	

C2.1.D_DSD	By Sex: Male	147	
C2.1.D_DSD	Sum of Sex disaggregates	300	
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	300	
C2.1.D_NGI	By Age/Sex: <15 Female	0	
C2.1.D_NGI	By Age/Sex: <15 Male	0	
C2.1.D_NGI	By Age/Sex: 15+ Female	153	
C2.1.D_NGI	By Age/Sex: 15+ Male	147	
C2.1.D_NGI	Sum of Age/Sex disaggregates	300	
C2.1.D_NGI	By Age: <15	0	
C2.1.D_NGI	By Age: 15+	300	
C2.1.D_NGI	Sum of Age disaggregates	300	
C2.1.D_NGI	By Sex: Female	153	
C2.1.D_NGI	By Sex: Male	147	
C2.1.D_NGI	Sum of Sex disaggregates	300	
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	240	
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	300	
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	300	840
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	147	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	153	



CARE_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	300	
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	150	1,100
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	0	
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	0	
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	0	
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	73	
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	0	
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	77	
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	150	
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	0	
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	150	
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	150	1,100
TX_CURR_TA	Aggregated Age/Sex: <1 Male	0	
TX_CURR_TA	Aggregated Age/Sex: <1 Female	0	
TX_CURR_TA	Aggregated Age/Sex: <15 Male	0	
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	73	
TX_CURR_TA	Aggregated Age/Sex: <15 Female	0	
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	77	
TX_CURR_TA	Sum of Aggregated Age/Sex <15	0	
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	150	
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	150	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	400	
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	0	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	0	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	196	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	0	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	0	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+	204	



	Female		
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	400	
TX_NEW_DSD	Pregnancy status	0	
TX_NEW_DSD	Breastfeeding status	0	
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	300	840

Implementing Mechanism Details

Mechanism ID: 13542	Mechanism Name: Programme National de Transfusion et Sécurité Sanguine (PNTS) / National Blood Safety Program
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Programme National de Transfusion et Sécurité Sanguine	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: PR/SR	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 300,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	300,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	50,000
----------------------------	--------



Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	13542		
Mechanism Name:	Programme National de Transfusion et Sécurité Sanguine (PNTS) /		
Prime Partner Name:	National Blood Safety Program		
	Programme National de Transfusion et Sécurité Sanguine		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
BS_COLL	Number of whole blood collections each year by the NBTS network	2,000		Redacted
BS_COLL	By: Number of whole blood donations screened for HIV in an NBTS network laboratory	20,000		Redacted
BS_COLL	By: Number of whole blood donations screened for HIV in an NBTS network laboratory that are identified as reactive for HIV	320		Redacted

Implementing Mechanism Details



Mechanism ID: 13476	Mechanism Name: Technical assistance in support of HIV prevention, care, and treatment programs and other infectious diseases that impact HIV-infected patients in the Democratic Republic of Congo in support of the President's Emergency Plan for AIDS Relief (PEPFAR)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: International Center for AIDS Care and Treatment Programs, Columbia University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 8,530,794	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	8,530,794

Sub Partner Name(s)

Action Contre la Faim	Armee du Salut	TBD
-----------------------	----------------	-----

Cross-Cutting Budget Attribution(s)

Motor Vehicles: Purchased	74,600
Motor Vehicles: Leased	19,000
Key Populations: MSM and TG	140,721
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information



Focus Area:	Monitoring and evaluation of MSM/TG programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for MSM/TG
Key Populations: FSW	281,442
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs
Food and Nutrition: Policy, Tools, and Service Delivery	325,000
Food and Nutrition: Commodities	125,000

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	13476		
Mechanism Name:	Technical assistance in support of HIV prevention, care, and treatment programs and other infectious diseases that impact HIV-infected patients		
Prime Partner Name:	in the Democratic Republic of Congo in support of the President's Emergency Plan for AIDS Relief (PEPFAR)		
	International Center for AIDS Care and Treatment Programs, Columbia University		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HBHC	1,676,268	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	92,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	1,198,185	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	727,440	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	818,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	1,809,804	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,363,597	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	PDTX	395,000	0
-----------	------	---------	---

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	1,943	1,943	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	244	244	Redacted
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	244	244	Redacted
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	244	244	Redacted
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	244	244	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	229	229	Redacted



SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	244	244	Redacted
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	6	6	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	244	244	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	244	244	Redacted
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	0	0	Redacted
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of	2,034	2,055	Redacted



	mother-to-child-transmission (MTCT) during pregnancy and delivery			
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	2,118	2,118	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	1,275	2,055	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	1,075	1,834	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	200	221	Redacted
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	759	0	Redacted
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	2,034	2,055	Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	1,275	2,055	Redacted
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	2,034		Redacted
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	2,118		Redacted
PMTCT_ARV_NGI	Life-long ART (including Option B+)	1,275		Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly	1,075		Redacted

	initiated on treatment during the current pregnancy			
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	200		Redacted
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	759		Redacted
PMTCT_ARV_NGI	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_NGI	Sum of Regimen disaggregates	2,034		Redacted
PMTCT_ARV_NGI	Sum of New and Current disaggregates	1,275		Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	137,556	137,556	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	141,318	141,318	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	287	292	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	1,831	1,826	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	2,118	2,118	Redacted
PMTCT_STAT_NG I	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	137,556		Redacted
PMTCT_STAT_NG I	Number of new ANC and L&D clients	141,318		Redacted
PMTCT_STAT_NG	By: Known positives at entry	287		Redacted



I				
PMTCT_STAT_NG I	By: Number of new positives identified	1,831		Redacted
PMTCT_STAT_NG I	Sum of Positives Status disaggregates	2,118		Redacted
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	2,000	2,000	Redacted
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,500	1,500	Redacted
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0	Redacted
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0	Redacted
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small	250	400	Redacted

	group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)			
KP_PREV_DSD	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	250	100	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	269,646	271,085	Redacted
HTC_TST_DSD	By Test Result: Negative	260,512	261,949	Redacted
HTC_TST_DSD	By Test Result: Positive	9,134	9,136	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	269,646	271,085	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	6,964		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	36,914		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	9,482		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	216,286		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	16,446		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	253,200		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	269,646		Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	269,646	271,085	Redacted
HTC_TST_NGI	By Test Result: Negative	260,512	261,949	Redacted



HTC_TST_NGI	By Test Result: Positive	9,234	9,136	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	269,746	271,085	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	6,964		Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	36,914		Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	9,482		Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	216,286		Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	16,446		Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	253,200		Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	269,646		Redacted
GEND_GBV_DSD	Number of people receiving post-GBV care	150	150	Redacted
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	21,799		Redacted
C2.1.D_DSD	By Age/Sex: <15 Female	1,660		Redacted
C2.1.D_DSD	By Age/Sex: <15 Male	974		Redacted
C2.1.D_DSD	By Age/Sex: 15+ Female	10,967		Redacted
C2.1.D_DSD	By Age/Sex: 15+ Male	8,198		Redacted
C2.1.D_DSD	Sum of Age/Sex disaggregates	21,799		Redacted
C2.1.D_DSD	By Age: <15	2,634		Redacted
C2.1.D_DSD	By Age: 15+	19,165		Redacted
C2.1.D_DSD	Sum of Age disaggregates	21,799		Redacted
C2.1.D_DSD	By Sex: Female	12,627		Redacted
C2.1.D_DSD	By Sex: Male	9,172		Redacted
C2.1.D_DSD	Sum of Sex disaggregates	21,799		Redacted
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	21,799		Redacted
C2.1.D_NGI	By Age/Sex: <15 Female	1,660		Redacted
C2.1.D_NGI	By Age/Sex: <15 Male	974		Redacted
C2.1.D_NGI	By Age/Sex: 15+ Female	10,967		Redacted
C2.1.D_NGI	By Age/Sex: 15+ Male	8,198		Redacted

C2.1.D_NGI	Sum of Age/Sex disaggregates	21,799		Redacted
C2.1.D_NGI	By Age: <15	2,634		Redacted
C2.1.D_NGI	By Age: 15+	19,165		Redacted
C2.1.D_NGI	Sum of Age disaggregates	21,799		Redacted
C2.1.D_NGI	By Sex: Female	12,627		Redacted
C2.1.D_NGI	By Sex: Male	9,172		Redacted
C2.1.D_NGI	Sum of Sex disaggregates	21,799		Redacted
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	21,799		Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	21,399	24,740	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,074		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	6,198		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,160		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	12,967		Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	21,399		Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	2,216	2,216	Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	2,216	2,216	Redacted
FN_THER_DSD	Aggregated Age: <18	1,551		Redacted
FN_THER_DSD	Aggregated Age: 18+	665		Redacted

FN_THER_DSD	Sum of Aggregated Age disaggregates	2,216		Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	860	860	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	2,118	2,118	Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	578	578	Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	282	282	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	860	860	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	85	85	Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	15,817	19,220	Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	33	8	Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	67	68	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	22		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	21		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	824		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	4,295		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	984		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	9,714		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	1,808		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	14,009		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex	15,817		Redacted



	disaggregates			
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	15,817	19,220	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	22		Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	21		Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	824		Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	4,295		Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	984		Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	9,714		Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	15,817		Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	1,808		Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	14,009		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	5,106	7,773	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	22		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	255		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,481		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	21		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	255		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	3,115		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	5,106		Redacted
TX_NEW_DSD	Pregnancy status	1,075	1,107	Redacted
TX_NEW_DSD	Breastfeeding status	796	324	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,288	3,289	Redacted

TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	3,050	4,109	Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	241		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,047		Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	321		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,729		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	102		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the	113		Redacted



	12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)			
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	0	5	Redacted
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	0	5	Redacted
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	0	0	Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	0	5	Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	244	244	Redacted
LAB_CAP_DSD	By clinical laboratories	244	244	Redacted
LAB_CAP_DSD	By Point-of-care testing sites	0	0	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	244	244	Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	0	0	Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	244	244	Redacted
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	2,232	2,232	Redacted
HRH_PRE	By Graduates: Doctors	0	0	Redacted
HRH_PRE	By Graduates: Nurses	2,135	2,135	Redacted



HRH_PRE	By Graduates: Midwives	97	97	Redacted
HRH_PRE	By Graduates: Social service workers	0	0	Redacted
HRH_PRE	By Graduates: Laboratory professionals	0	0	Redacted
HRH_PRE	By Graduates: Other	0	0	Redacted
HRH_PRE	Sum of Graduates disaggreagtes	2,232	2,232	Redacted
HRH_PRE	By new graduates who are licensed and registered: Doctors	0	0	Redacted
HRH_PRE	By new graduates who are licensed and registered: Nurses	2,135	2,135	Redacted
HRH_PRE	By new graduates who are licensed and registered: Midwives	97	97	Redacted
HRH_PRE	By new graduates who are licensed and registered: Social service workers	0	0	Redacted
HRH_PRE	By new graduates who are licensed and registered: Laboratorians	0	0	Redacted
HRH_PRE	By new graduates who are licensed and registered: Other (where applicable)	0	0	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	21,399	24,740	Redacted

Implementing Mechanism Details

Mechanism ID: 13338	Mechanism Name: Technical Assistance in Support of the President's Emergency Plan for AIDS Relief
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Tulane University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Approved



Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	13338		
Mechanism Name:	Technical Assistance in Support of the President's Emergency Plan for AIDS Relief		
Prime Partner Name:	Tulane University		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details



Mechanism ID: 13183	Mechanism Name: Programme National de Lutte contre le VIH/SIDA et IST/ National AIDS Control Program
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Programme National de Lutte contre le VIH/SIDA et IST	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: PR/SR	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 250,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	250,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	100,000
----------------------------	---------

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	13183
Mechanism Name:	Programme National de Lutte contre le VIH/SIDA et IST/ National AIDS Control Program
Prime Partner Name:	Programme National de Lutte contre le VIH/SIDA et IST



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13094	Mechanism Name: Association of Public Health Laboratories Centrally funded CoAG
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Association of Public Health Laboratories	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 200,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	200,000

Sub Partner Name(s)

(No data provided.)



Cross-Cutting Budget Attribution(s)

Human Resources for Health	200,000
----------------------------	---------

Key Issues

Workplace Programs

Budget Code Information

Mechanism ID:	13094		
Mechanism Name:	Association of Public Health Laboratories Centrally funded CoAG		
Prime Partner Name:	Association of Public Health Laboratories		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	200,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	6	6	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery	0	0	Redacted



	(DSD)			
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Technical	0	0	Redacted



	Assistance-only (TA)			
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	6	6	Redacted
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	5	6	Redacted
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	0	0	Redacted
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	5	6	Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	5	6	Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	6	6	Redacted
LAB_CAP_DSD	By clinical laboratories	0	6	Redacted
LAB_CAP_DSD	By Point-of-care testing sites	6	0	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	0	0	Redacted



LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	6	6	Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	6	6	Redacted

Implementing Mechanism Details

Mechanism ID: 13017	Mechanism Name: Global Laboratory Capacity Strengthening Program
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: American Society for Microbiology	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 150,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	150,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

TB



Budget Code Information

Mechanism ID:	13017		
Mechanism Name:	Global Laboratory Capacity Strengthening Program		
Prime Partner Name:	American Society for Microbiology		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	150,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	4	4	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery	0	0	Redacted



	(DSD)			
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	0	0	Redacted



SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	4	4	Redacted
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	0	4	Redacted
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	0	0	Redacted
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	0	4	Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	0	4	Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	4	4	Redacted
LAB_CAP_DSD	By clinical laboratories	4	4	Redacted
LAB_CAP_DSD	By Point-of-care testing sites	0	0	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	0	0	Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	4	4	Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	4	4	Redacted

Implementing Mechanism Details

Mechanism ID: 13010	Mechanism Name: Integrated Health Project
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: Management Sciences for Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No



Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 1,513,500	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	1,263,500
GHP-USAID	250,000

Sub Partner Name(s)

International Rescue Committee	Overseas Strategic Consulting	
--------------------------------	-------------------------------	--

Cross-Cutting Budget Attribution(s)

Gender: GBV	65,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Key Populations: FSW	35,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention



Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs

Key Issues

- Malaria (PMI)
- Child Survival Activities
- Safe Motherhood
- TB
- Family Planning

Budget Code Information

Mechanism ID: 13010			
Mechanism Name: Integrated Health Project			
Prime Partner Name: Management Sciences for Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	201,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	289,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	129,100	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and	HLAB	44,500	0



Systems			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	41,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	101,210	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	417,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	190,690	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	100,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	368	373



SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	45	45
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	45	45
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	62	62
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	62	62
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	53	53
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	0	2
SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	2	2
SITE_SUPP	By program area/support type: Key	0	0



	Populations Prevention Technical Assistance-only (TA)		
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	62	62
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	62	62
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	0	0
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	152	194
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	180	208
PMTCT_ARV_DSD	Life-long ART (including Option B+)	64	194
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	54	190
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	10	4
PMTCT_ARV_DSD	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0
PMTCT_ARV_DSD	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	88	0



PMTCT_ARV_DSD	Single-dose nevirapine (with or without tail)	0	0
PMTCT_ARV_DSD	Sum of Regimen Type disaggregates	152	194
PMTCT_ARV_DSD	Sum of New and Current disaggregates	64	194
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	152	
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	180	
PMTCT_ARV_NGI	Life-long ART (including Option B+)	64	
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	54	
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	10	
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	88	
PMTCT_ARV_NGI	Single-dose nevirapine (with or without tail)	0	
PMTCT_ARV_NGI	Sum of Regimen disaggregates	152	
PMTCT_ARV_NGI	Sum of New and Current disaggregates	64	
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	17,722	21,894
PMTCT_STAT_DSD	Number of new ANC and L&D clients	20,605	24,007
PMTCT_STAT_DSD	By: Known positives at entry	46	50
PMTCT_STAT_DSD	By: Number of new positives identified	134	158
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	180	208
PMTCT_STAT_NGI	Number of pregnant women with known HIV status (includes women who were tested for	17,722	



	HIV and received their results)		
PMTCT_STAT_NGI	Number of new ANC and L&D clients	20,605	
PMTCT_STAT_NGI	By: Known positives at entry	46	
PMTCT_STAT_NGI	By: Number of new positives identified	134	
PMTCT_STAT_NGI	Sum of Positives Status disaggregates	180	
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	0	11,018
PP_PREV_DSD	Age/sex: 10-14 Male	0	7
PP_PREV_DSD	Age/sex: 15-19 Male	0	401
PP_PREV_DSD	Age/sex: 20-24 Male	0	1,418
PP_PREV_DSD	Age/sex: 25-49 Male	0	1,518
PP_PREV_DSD	Age/sex: 50+ Male	0	153
PP_PREV_DSD	Age/sex: 10-14 Female	0	81
PP_PREV_DSD	Age/sex: 15-19 Female	0	692
PP_PREV_DSD	Age/sex: 20-24 Female	0	2,817
PP_PREV_DSD	Age/sex: 25-49 Female	0	2,420
PP_PREV_DSD	Age/sex: 50+ Female	0	1,511
PP_PREV_DSD	Sum of Age/Sex disaggregates	0	11,018
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	60	430
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	60	430
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or	0	0



	small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)		
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0
KP_PREV_DSD	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	30,330	35,000
HTC_TST_DSD	By Test Result: Negative	29,724	34,300
HTC_TST_DSD	By Test Result: Positive	606	700
HTC_TST_DSD	Sum of Test Result disaggregates	30,330	35,000
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	300	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	7,463	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	680	



HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	21,887	
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	980	
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	29,350	
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	30,330	
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	30,330	35,000
HTC_TST_NGI	By Test Result: Negative	29,724	34,300
HTC_TST_NGI	By Test Result: Positive	606	700
HTC_TST_NGI	Sum of Test Result disaggregates	30,330	35,000
HTC_TST_NGI	Aggregated Age/sex: <15 Male	300	
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	7,463	
HTC_TST_NGI	Aggregated Age/sex: <15 Female	680	
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	21,887	
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	980	
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	29,350	
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	30,330	
GEND_GBV_DSD	Number of people receiving post-GBV care	150	180
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	696	
C2.1.D_DSD	By Age/Sex: <15 Female	55	
C2.1.D_DSD	By Age/Sex: <15 Male	20	
C2.1.D_DSD	By Age/Sex: 15+ Female	497	
C2.1.D_DSD	By Age/Sex: 15+ Male	124	
C2.1.D_DSD	Sum of Age/Sex disaggregates	696	
C2.1.D_DSD	By Age: <15	75	
C2.1.D_DSD	By Age: 15+	621	
C2.1.D_DSD	Sum of Age disaggregates	696	
C2.1.D_DSD	By Sex: Female	547	
C2.1.D_DSD	By Sex: Male	149	
C2.1.D_DSD	Sum of Sex disaggregates	696	

C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	696	
C2.1.D_NGI	By Age/Sex: <15 Female	55	
C2.1.D_NGI	By Age/Sex: <15 Male	20	
C2.1.D_NGI	By Age/Sex: 15+ Female	497	
C2.1.D_NGI	By Age/Sex: 15+ Male	124	
C2.1.D_NGI	Sum of Age/Sex disaggregates	696	
C2.1.D_NGI	By Age: <15	75	
C2.1.D_NGI	By Age: 15+	621	
C2.1.D_NGI	Sum of Age disaggregates	696	
C2.1.D_NGI	By Sex: Female	547	
C2.1.D_NGI	By Sex: Male	149	
C2.1.D_NGI	Sum of Sex disaggregates	696	
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	623	
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	696	
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	696	815
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	9	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	162	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	26	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	499	
CARE_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	696	
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting	47	68



	period		
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	180	208
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	28	42
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	19	26
PMTCT_EID_DSD	Sum of Infant Age disaggregates	47	68
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	2	2
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	175	364
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	24	7
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	76	84
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	1	
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	3	
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	2	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	40	
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	6	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	127	
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	8	
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	167	
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	175	
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	175	671
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	1	
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	3	



TX_CURR_NGI	Aggregated Age/Sex: <15 Male	2	
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	40	
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	6	
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	127	
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	175	
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	8	
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	167	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	115	339
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	2	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	5	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	30	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	2	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	5	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	75	
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	115	
TX_NEW_DSD	Pregnancy status	54	190
TX_NEW_DSD	Breastfeeding status	20	25
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	115	302
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	139	327
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	7	
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	108	



TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	7	
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	132	
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	55	
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	70	
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	0	2
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	0	2
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	0	0
LAB_ACC_DSD	Sum of Support Type disaggregates	0	2
LAB_CAP_DSD	Number of PEPFAR-supported testing	62	62



	facilities with capacity to perform clinical laboratory tests		
LAB_CAP_DSD	By clinical laboratories	62	62
LAB_CAP_DSD	By Point-of-care testing sites	0	0
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	62	62
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	0	0
LAB_CAP_DSD	Sum of Site Support Type disaggregates	62	62
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	696	815

Implementing Mechanism Details

Mechanism ID: 11054	Mechanism Name: HIV activities in the DRC Armed Forces
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: Population Services International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 2,420,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	2,420,000

Sub Partner Name(s)

FHI 360		
---------	--	--



Cross-Cutting Budget Attribution(s)

Gender: GBV	150,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

Key Issues

- Malaria (PMI)
- Child Survival Activities
- Military Population
- Mobile Population
- Safe Motherhood
- TB
- Workplace Programs
- End-of-Program Evaluation
- Family Planning

Budget Code Information

Mechanism ID:	11054
----------------------	--------------



Mechanism Name: HIV activities in the DRC Armed Forces			
Prime Partner Name: Population Services International			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	320,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	230,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	70,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	230,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	200,000	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	350,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	120,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	21	15
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	5	3
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	3	3
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	3	3
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	5	3
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	5	3
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	36,000	36,000
PP_PREV_DSD	Total number of people in the target population	419,954	251,972



PP_PREV_DSD	Age/sex: 10-14 Male	0	0
PP_PREV_DSD	Age/sex: 15-19 Male	3,200	3,200
PP_PREV_DSD	Age/sex: 20-24 Male	8,000	8,000
PP_PREV_DSD	Age/sex: 25-49 Male	14,000	14,000
PP_PREV_DSD	Age/sex: 50+ Male	20	20
PP_PREV_DSD	Age/sex: 10-14 Female	0	0
PP_PREV_DSD	Age/sex: 15-19 Female	800	800
PP_PREV_DSD	Age/sex: 20-24 Female	3,000	3,000
PP_PREV_DSD	Age/sex: 25-49 Female	6,970	6,970
PP_PREV_DSD	Age/sex: 50+ Female	10	10
PP_PREV_DSD	Sum of Age/Sex disaggregates	36,000	36,000
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	20,000	20,000
HTC_TST_DSD	By Test Result: Negative	18,800	18,800
HTC_TST_DSD	By Test Result: Positive	1,200	1,200
HTC_TST_DSD	Sum of Test Result disaggregates	20,000	20,000
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	700	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	13,300	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	300	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	5,700	
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	1,000	
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	19,000	
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	20,000	
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	20,000	20,000
HTC_TST_NGI	By Test Result: Negative	18,800	18,800
HTC_TST_NGI	By Test Result: Positive	1,200	1,200



HTC_TST_NGI	Sum of Test Result disaggregates	20,000	20,000
HTC_TST_NGI	Aggregated Age/sex: <15 Male	700	
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	13,300	
HTC_TST_NGI	Aggregated Age/sex: <15 Female	300	
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	5,700	
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	1,000	
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	19,000	
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	20,000	
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	45	
C2.1.D_DSD	By Age/Sex: <15 Female	0	
C2.1.D_DSD	By Age/Sex: <15 Male	0	
C2.1.D_DSD	By Age/Sex: 15+ Female	13	
C2.1.D_DSD	By Age/Sex: 15+ Male	32	
C2.1.D_DSD	Sum of Age/Sex disaggregates	45	
C2.1.D_DSD	By Age: <15	0	
C2.1.D_DSD	By Age: 15+	45	
C2.1.D_DSD	Sum of Age disaggregates	45	
C2.1.D_DSD	By Sex: Female	13	
C2.1.D_DSD	By Sex: Male	32	
C2.1.D_DSD	Sum of Sex disaggregates	45	
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	45	
C2.1.D_NGI	By Age/Sex: <15 Female	0	
C2.1.D_NGI	By Age/Sex: <15 Male	0	
C2.1.D_NGI	By Age/Sex: 15+ Female	13	
C2.1.D_NGI	By Age/Sex: 15+ Male	32	
C2.1.D_NGI	Sum of Age/Sex disaggregates	45	
C2.1.D_NGI	By Age: <15	0	
C2.1.D_NGI	By Age: 15+	45	
C2.1.D_NGI	Sum of Age disaggregates	45	
C2.1.D_NGI	By Sex: Female	13	



C2.1.D_NGI	By Sex: Male	32	
C2.1.D_NGI	Sum of Sex disaggregates	45	
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	45	
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	45	
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	45	1,187
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	32	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	13	
CARE_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	45	
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	0	
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	0	
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	0	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	0	
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	0	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	0	
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	0	
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	0	
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	0	
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	0	501
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	0	



TX_CURR_NGI	Aggregated Age/Sex: <1 Female	3	
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	0	
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	0	
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	0	
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	0	
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	0	
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	0	
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	0	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	0	456
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	0	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	0	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	0	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	0	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	0	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	0	
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	0	
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	45	1,187

Implementing Mechanism Details

Mechanism ID: 10612	Mechanism Name: PROVISION OF CAPACITY BUILDING TO EMERGENCY PLAN PARTNERS AND TO LOCAL ORGANIZATIONS IN THE DEMOCRATIC REPUBLIC OF CONGO FOR HIV/AIDS ACTIVITIES UNDER THE PRESIDENT'S EMERGENCY PLAN FOR AIDS RELIEF (PEPFAR)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement

Approved



Prime Partner Name: Kinshasa School of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GAP	0

Sub Partner Name(s)

Fondation Femmes Plus	National AIDS & STD Control Program	
-----------------------	-------------------------------------	--

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

End-of-Program Evaluation

Budget Code Information

Mechanism ID:	10612
Mechanism Name:	PROVISION OF CAPACITY BUILDING TO EMERGENCY PLAN PARTNERS AND TO LOCAL ORGANIZATIONS IN THE DEMOCRATIC REPUBLIC OF CONGO FOR HIV/AIDS ACTIVITIES UNDER THE PRESIDENT'S EMERGENCY PLAN FOR AIDS RELIEF (PEPFAR)
Prime Partner Name:	Kinshasa School of Public Health



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	4		Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	1		Redacted
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	0		Redacted
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	0		Redacted
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	0		Redacted
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery	0		Redacted



	(DSD)			
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	0		Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	0		Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	0		Redacted
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	0		Redacted
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	0		Redacted
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	0		Redacted
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	0		Redacted
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	1		Redacted
SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	0		Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	1		Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	0		Redacted
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	0		Redacted
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	0		Redacted



SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	1		Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	0		Redacted
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	0		Redacted
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	0		Redacted
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	400,000		Redacted
PP_PREV_DSD	Total number of people in the target population	500,000		Redacted
PP_PREV_DSD	Age/sex: 10-14 Male	11,200		Redacted
PP_PREV_DSD	Age/sex: 15-19 Male	14,100		Redacted
PP_PREV_DSD	Age/sex: 20-24 Male	155,600		Redacted
PP_PREV_DSD	Age/sex: 25-49 Male	65,048		Redacted
PP_PREV_DSD	Age/sex: 50+ Male	25,434		Redacted
PP_PREV_DSD	Age/sex: 10-14 Female	2,200		Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	74,800		Redacted
PP_PREV_DSD	Age/sex: 20-24 Female	32,000		Redacted
PP_PREV_DSD	Age/sex: 25-49 Female	14,552		Redacted
PP_PREV_DSD	Age/sex: 50+ Female	5,066		Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	400,000		Redacted
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	2,400		Redacted
KP_PREV_DSD	By key population type: Female sex	2,320		Redacted



	workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)			
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0		Redacted
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0		Redacted
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	80		Redacted
KP_PREV_DSD	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum	0		Redacted

	standards required)			
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	857		Redacted
HTC_TST_DSD	By Test Result: Negative	831		Redacted
HTC_TST_DSD	By Test Result: Positive	26		Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	857		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	29		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	4		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	824		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	4		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	853		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	857		Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	857		Redacted
HTC_TST_NGI	By Test Result: Negative	831		Redacted
HTC_TST_NGI	By Test Result: Positive	26		Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	857		Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	0		Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	29		Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	4		Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	824		Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	4		Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	853		Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	857		Redacted



HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	32		Redacted
HRH_PRE	By Graduates: Doctors	17		Redacted
HRH_PRE	By Graduates: Nurses	0		Redacted
HRH_PRE	By Graduates: Midwives	0		Redacted
HRH_PRE	By Graduates: Social service workers	0		Redacted
HRH_PRE	By Graduates: Laboratory professionals	7		Redacted
HRH_PRE	By Graduates: Other	8		Redacted
HRH_PRE	Sum of Graduates disaggreagtes	32		Redacted
HRH_PRE	By new graduates who are licensed and registered: Doctors	17		Redacted
HRH_PRE	By new graduates who are licensed and registered: Nurses	0		Redacted
HRH_PRE	By new graduates who are licensed and registered: Midwives	0		Redacted
HRH_PRE	By new graduates who are licensed and registered: Social service workers	0		Redacted
HRH_PRE	By new graduates who are licensed and registered: Laboratorians	7		Redacted
HRH_PRE	By new graduates who are licensed and registered: Other (where applicable)	8		Redacted

Implementing Mechanism Details

Mechanism ID: 7500	Mechanism Name: AIDS Support and Technical Resources (AIDSTAR) - INTEGRATED HIV/AIDS PROGRAM IN DRC (ProVIC: Program de VIH Intégré au Congo)
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: Program for Appropriate Technology in Health	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 4,400,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	3,451,546
GHP-USAID	948,454

Sub Partner Name(s)

Chemonics International	Elizabeth Glaser Pediatric AIDS Foundation	International HIV/AIDS Alliance
-------------------------	--	---------------------------------

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	100,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Food and Nutrition: Commodities	120,000
Key Populations: FSW	100,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Monitoring and evaluation of SW programs
Education	300,000



Human Resources for Health	176,000
----------------------------	---------

Key Issues

- Child Survival Activities
- Mobile Population
- Safe Motherhood
- TB
- Family Planning

Budget Code Information

Mechanism ID:	7500		
Mechanism Name:	AIDS Support and Technical Resources (AIDSTAR) - INTEGRATED		
Prime Partner Name:	HIV/AIDS PROGRAM IN DRC (ProVIC: Program de VIH Intégré au Congo) Program for Appropriate Technology in Health		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	900,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	450,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	250,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	HVSI	20,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	387,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	950,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXD	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	673,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	570,000	0

Implementing Mechanism Indicator Information



Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	1,477	1,275
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	115	115
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	112	112
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	101	101
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	115	115
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	112	112
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	112	112
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	113	113
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: VMMC Technical Assistance-only (TA)	131	131
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	134	134



SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	134	134
SITE_SUPP	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	202	0
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	112	112
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	115	115
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	0	0
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	1,784	1,188
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	1,857	1,238
PMTCT_ARV_DSD	Life-long ART (including Option B+)	790	1,188
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	582	1,088
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current	208	100



	pregnancy		
PMTCT_ARV_DSD	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0
PMTCT_ARV_DSD	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	994	0
PMTCT_ARV_DSD	Single-dose nevirapine (with or without tail)	0	0
PMTCT_ARV_DSD	Sum of Regimen Type disaggregates	1,784	1,188
PMTCT_ARV_DSD	Sum of New and Current disaggregates	790	1,188
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	1,784	
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	1,857	
PMTCT_ARV_NGI	Life-long ART (including Option B+)	790	
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	582	
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	208	
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	994	
PMTCT_ARV_NGI	Single-dose nevirapine (with or without tail)	0	
PMTCT_ARV_NGI	Sum of Regimen disaggregates	1,784	
PMTCT_ARV_NGI	Sum of New and Current disaggregates	790	
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for	77,397	51,294



	HIV and received their results)		
PMTCT_STAT_DSD	Number of new ANC and L&D clients	79,791	52,880
PMTCT_STAT_DSD	By: Known positives at entry	208	133
PMTCT_STAT_DSD	By: Number of new positives identified	1,649	1,105
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	1,857	1,238
PMTCT_STAT_NGI	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	77,397	
PMTCT_STAT_NGI	Number of new ANC and L&D clients	79,791	
PMTCT_STAT_NGI	By: Known positives at entry	208	
PMTCT_STAT_NGI	By: Number of new positives identified	1,649	
PMTCT_STAT_NGI	Sum of Positives Status disaggregates	1,857	
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	59,715	39,810
PP_PREV_DSD	Total number of people in the target population	628,558	41,905
PP_PREV_DSD	Age/sex: 10-14 Male	208	122
PP_PREV_DSD	Age/sex: 15-19 Male	2,873	1,569
PP_PREV_DSD	Age/sex: 20-24 Male	4,685	2,609
PP_PREV_DSD	Age/sex: 25-49 Male	8,790	5,771
PP_PREV_DSD	Age/sex: 50+ Male	781	551
PP_PREV_DSD	Age/sex: 10-14 Female	267	175
PP_PREV_DSD	Age/sex: 15-19 Female	6,298	3,741
PP_PREV_DSD	Age/sex: 20-24 Female	12,394	7,510
PP_PREV_DSD	Age/sex: 25-49 Female	22,582	17,181
PP_PREV_DSD	Age/sex: 50+ Female	837	581
PP_PREV_DSD	Sum of Age/Sex disaggregates	59,715	39,810
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards	2,906	1,937



	required		
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	2,394	1,588
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	9	13
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	270	179
KP_PREV_DSD	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	233	157
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	91,055	61,035



HTC_TST_DSD	By Test Result: Negative	88,439	59,300
HTC_TST_DSD	By Test Result: Positive	2,616	1,735
HTC_TST_DSD	Sum of Test Result disaggregates	91,055	61,035
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	496	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	10,077	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,172	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	79,310	
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	1,668	
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	89,387	
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	91,055	
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	91,055	61,035
HTC_TST_NGI	By Test Result: Negative	88,439	59,300
HTC_TST_NGI	By Test Result: Positive	2,616	1,735
HTC_TST_NGI	Sum of Test Result disaggregates	91,055	61,035
HTC_TST_NGI	Aggregated Age/sex: <15 Male	496	
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	10,077	
HTC_TST_NGI	Aggregated Age/sex: <15 Female	1,172	
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	79,310	
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	1,668	
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	89,387	
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	91,055	
GEND_GBV_DSD	Number of people receiving post-GBV care	1,242	621
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	7,512	0
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	9,997	



C2.1.D_DSD	By Age/Sex: <15 Female	124	
C2.1.D_DSD	By Age/Sex: <15 Male	65	
C2.1.D_DSD	By Age/Sex: 15+ Female	7,806	
C2.1.D_DSD	By Age/Sex: 15+ Male	2,002	
C2.1.D_DSD	Sum of Age/Sex disaggregates	9,997	
C2.1.D_DSD	By Age: <15	189	
C2.1.D_DSD	By Age: 15+	9,808	
C2.1.D_DSD	Sum of Age disaggregates	9,997	
C2.1.D_DSD	By Sex: Female	7,926	
C2.1.D_DSD	By Sex: Male	2,071	
C2.1.D_DSD	Sum of Sex disaggregates	9,997	
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	9,997	
C2.1.D_NGI	By Age/Sex: <15 Female	124	
C2.1.D_NGI	By Age/Sex: <15 Male	65	
C2.1.D_NGI	By Age/Sex: 15+ Female	7,806	
C2.1.D_NGI	By Age/Sex: 15+ Male	2,002	
C2.1.D_NGI	Sum of Age/Sex disaggregates	9,997	
C2.1.D_NGI	By Age: <15	7,926	
C2.1.D_NGI	By Age: 15+	2,071	
C2.1.D_NGI	Sum of Age disaggregates	9,997	
C2.1.D_NGI	By Sex: Female	7,926	
C2.1.D_NGI	By Sex: Male	2,071	
C2.1.D_NGI	Sum of Sex disaggregates	9,997	
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	2,183	
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	9,997	
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count	1,146	2,394

	OR viral load		
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	19	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	583	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	36	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	2,273	
CARE_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	2,911	
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	182	
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	182	
FN_THER_DSD	Aggregated Age: <18	45	
FN_THER_DSD	Aggregated Age: 18+	137	
FN_THER_DSD	Sum of Aggregated Age disaggregates	182	
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	743	557
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	1,857	1,238
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	371	334
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	372	223
PMTCT_EID_DSD	Sum of Infant Age disaggregates	743	557
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	15	11
TX_CURR_DSD	Number of adults and children receiving	2,889	1,577



	antiretroviral therapy (ART)		
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	18	2
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	82	84
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	17	
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	17	
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	27	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	489	
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	45	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	2,328	
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	72	
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	2,817	
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	2,889	
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	2,889	1,731
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	17	
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	17	
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	27	
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	489	
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	45	
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	2,328	
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	2,889	
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	72	
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	2,817	
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	241	154
TX_CURR_TA	Aggregated Age/Sex: <1 Male	1	
TX_CURR_TA	Aggregated Age/Sex: <1 Female	1	
TX_CURR_TA	Aggregated Age/Sex: <15 Male	6	
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	40	



TX_CURR_TA	Aggregated Age/Sex: <15 Female	4	
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	191	
TX_CURR_TA	Sum of Aggregated Age/Sex <15	10	
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	231	
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	241	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,748	1,286
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	8	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	423	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	213	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	8	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	441	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	671	
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,748	
TX_NEW_DSD	Pregnancy status	582	1,088
TX_NEW_DSD	Breastfeeding status	0	0
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	177	874
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	235	1,092
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	46	
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	131	
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated	61	



	ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	174	
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	471	
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	628	
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	113	113
LAB_CAP_DSD	By clinical laboratories	80	80
LAB_CAP_DSD	By Point-of-care testing sites	33	33
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	113	113
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	0	0
LAB_CAP_DSD	Sum of Site Support Type disaggregates	113	113
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count	1,146	2,394

Approved



	OR viral load		
--	---------------	--	--



**Agency Information - Costs of Doing Business
U.S. Agency for International Development**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Planned Amount As Of Last Q1	Cost of Doing Business Category Total	Applied Pipeline
Computers/IT Services			0	Redacted	0	0
ICASS			0	Redacted	0	0
Management Meetings/Professional Development			0	Redacted	0	0
Non-ICASS Administrative Costs			0	Redacted	0	0
Staff Program Travel		71,589	0	Redacted	71,589	0
USG Staff Salaries and Benefits		1,428,411	0	Redacted	1,428,411	0
Total	0	1,500,000	0	0	1,500,000	0

U.S. Agency for International Development Other Costs Details

Category	Item	Funding Source	Description	Planned Amount As Of Last Q1	Amount	Applied Pipeline
Computers/IT Services		GHP-USAID		Redacted	0	0
ICASS		GHP-USAID		Redacted	0	0
Management		GHP-USAID		Redacted	0	0



Meetings/Professional Development						
Non-ICASS Administrative Costs		GHP-USAID	Office Lease: 42,598.00; Utilities: 21,000.00; Phone/Internet: \$40,500.00; Office Supplies: \$5,000.00; Program Design & Learning \$54,602.00	Redacted	0	0

U.S. Department of Defense

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Planned Amount As Of Last Q1	Cost of Doing Business Category Total	Applied Pipeline
Capital Security Cost Sharing		0		Redacted	0	0
Computers/IT Services		0		Redacted	0	0
ICASS		0		Redacted	0	0
Management		0		Redacted	0	0



Meetings/Professional Development						
Staff Program Travel				Redacted	0	0
USG Staff Salaries and Benefits				Redacted	0	0
Total	0	0	0	0	0	0

U.S. Department of Defense Other Costs Details

Category	Item	Funding Source	Description	Planned Amount As Of Last Q1	Amount	Applied Pipeline
Capital Security Cost Sharing		GHP-State		Redacted	0	0
Computers/IT Services		GHP-State		Redacted	0	0
ICASS		GHP-State		Redacted	0	0
Management Meetings/Professional Development		GHP-State		Redacted	0	0

U.S. Department of Health and Human Services/Centers for Disease Control and Prevention

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Planned Amount As Of Last Q1	Cost of Doing Business Category Total	Applied Pipeline
Capital Security Cost Sharing		250,000		Redacted	250,000	0



Computers/IT Services		30,000		Redacted	30,000	0
ICASS		735,600		Redacted	735,600	0
Management Meetings/Professional Development		217,000		Redacted	217,000	0
Non-ICASS Administrative Costs		865,375		Redacted	865,375	0
Staff Program Travel	0	300,000		Redacted	300,000	0
USG Staff Salaries and Benefits	825,000	977,025		Redacted	1,802,025	0
Total	825,000	3,375,000	0	0	4,200,000	0

U.S. Department of Health and Human Services/Centers for Disease Control and Prevention Other Costs Details

Category	Item	Funding Source	Description	Planned Amount As Of Last Q1	Amount	Applied Pipeline
Capital Security Cost Sharing		GHP-State		Redacted	250,000	0
Computers/IT Services		GHP-State		Redacted	30,000	0
ICASS		GHP-State		Redacted	735,600	0
Management Meetings/Professional Development		GHP-State		Redacted	217,000	0
Non-ICASS Administrative Costs		GHP-State	Shipping 22,000.00,	Redacted	865,375	0



			Residential utilities 30,000.00 ,Residential Internet 3,000.00;Other contractual services45,000.00;Telephone 26,400.00;Contractual services (Comforce),345.00;Supplies 25,000.00;Fuel 16,691.00;Office security upgrade 100,000.00;Non-ICASS Vehicle 120,000.00;Equipments90,939.00			
--	--	--	--	--	--	--



--	--	--	--	--	--	--

U.S. Department of State

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Planned Amount As Of Last Q1	Cost of Doing Business Category Total	Applied Pipeline
Management Meetings/Professional Development		153,412		Redacted	153,412	0
Non-ICASS Administrative Costs		30,000		Redacted	30,000	0
Staff Program Travel		55,000		Redacted	55,000	0
USG Staff Salaries and Benefits		61,588		Redacted	61,588	0
Total	0	300,000	0	0	300,000	0

U.S. Department of State Other Costs Details

Category	Item	Funding Source	Description	Planned Amount As Of Last Q1	Amount	Applied Pipeline
Management Meetings/Professional Development		GHP-State		Redacted	153,412	0
Non-ICASS Administrative Costs		GHP-State		Redacted	30,000	0

Approved

